Document:

Exhibit 10.11

 

Certain confidential information contained in this document, marked
by brackets as [***], has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
In addition, certain personally identifiable information contained in this document, marked by brackets as [***], has been omitted from
this exhibit pursuant to Item 601(a)(6) under Regulation S-K.

 

CLINICAL AND COMMERCIAL MANUFACTURING AGREEMENT

 

dated October 15th, 2018

 

by and between

 

Richter-Helm BioLogics GmbH & Co. KG 

 

and

 

Merck KGaA

 

    i

     

    

 

TABLE OF CONTENTS

 

		 	Page
		 	 
	Article 1 DEFINITIONS	 	1
	 	 	 
	Article 2 MANUFACTURER’S OBLIGATIONS	 	8
	 	 	 
	Article 3 INTELLECTUAL PROPERTY	 	11
	 	 	 
	Article 4 FORECASTS AND ORDERS	 	12
	 	 	 
	Article 5 DELIVERY OF PRODUCT	 	14
	 	 	 
	Article 6 PRICE	 	17
	 	 	 
	Article 7 INVOICES AND PAYMENT	 	20
	 	 	 
	Article 8 QUALITY ASSURANCE	 	20
	 	 	 
	Article 9 DEFECTIVE PRODUCTS AND DEFECTIVE SERVICES	 	21
	 	 	 
	Article 10 PRODUCT LICENSES	 	24
	 	 	 
	Article 11 TRIAL AUTHORIZATION	 	24
	 	 	 
	Article 12 CHANGES TO PRODUCT SPECIFICATIONS	 	24
	 	 	 
	Article 13 QUALITY & REGULATORY COMPLIANCE	 	25
	 	 	 
	Article 14 OPERATIONAL MANAGEMENT; STEERING COMMITTEE	 	28
	 	 	 
	Article 15 PRODUCT COMPLAINTS AND ADVERSE EVENTS	 	28
	 	 	 
	Article 16 CONFIDENTIALITY AND DATA PROTECTION	 	29
	 	 	 
	Article 17 WARRANTIES	 	30
	 	 	 
	Article 18 INDEMNITY	 	32
	 	 	 
	Article 19 TERM AND TERMINATION	 	33
	 	 	 
	Article 20 EFFECTS OF TERMINATION	 	35
	 	 	 
	Article 21 DISASTER RECOVERY AND BUSINESS CONTINUITY	 	36
	 	 	 
	Article 22 DISPUTE RESOLUTION	 	36
	 	 	 
	Article 23 MISCELLANEOUS PROVISIONS	 	37

 

    ii

     

    

 

CLINICAL AND COMMERCIAL MANUFACTURING AGREEMENT

 

This CLINICAL AND COMMERCIAL MANUFACTURING AGREEMENT
(the “Agreement”) is made as of October 15th, 2018 (the “Effective Date”) by and between Richter
Helm Biologics GmbH & Co. KG, a corporation organized under the laws of Germany having a place of business at [***] (“Manufacturer”),
and Merck KGaA, a corporation organized under the laws of Germany having a place of business at Frankfurter Straße 250, 64293 Darmstadt,
Germany (“Merck”). Manufacturer and Merck may be referred to herein as a “Party” or, collectively,
as “Parties.”

 

RECITALS

 

WHEREAS, Merck, its Affiliates
or a Merck’s designated third party are engaged in the discovery, development, manufacture and sale of pharmaceuticals products
and intend to conduct clinical trials of the Products (as defined below);

 

WHEREAS, in order to ensure
a continuous manufacturing and a reliable supply of the Product for the development of Merck’s Anti IL-17 A/F Nanobody®, an
investigational therapy for the potential treatment of inflammatory deseases, in a phase III study in plaque psoriasis, and to secure
enough manufacturing capacity after the potential launch of the Product Merck is interested in entering in an agreement with Manufacturer
for clinical and commercial manufacturing services;

 

WHEREAS, Manufacturer has the
requisite infrastructure, licenses, permits and capabilities, including trained and experienced personnel and technical skills, to manufacture
and supply the Product (as defined below) to Merck for the aforesaid purposes and in accordance with this Agreement;

 

NOW, THEREFORE, in consideration
of the mutual promises, covenants and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, and intending to be legally bound, the Parties hereby agree as follows:

 

Article
1

DEFINITIONS

 

Definitions contained in this
Agreement are applicable to the singular as well as the plural forms of such terms. Unless otherwise specifically provided herein, the
following terms shall have the following meanings:

 

		1.1	“Adverse Event” means any of: an “adverse drug
experience,” a “life-threatening adverse drug experience,” a “serious adverse drug experience,” or an “unexpected
adverse drug experience,” as those terms are defined at either 21 C.F.R. § 312.32 or 21 C.F.R. § 314.80 or other applicable
or other regulations and laws”.

 

		1.2	“Affiliate” means a person or entity that Controls, is
Controlled by or is under common Control with a Party, but only for so long as such control exists. “Control” means
the ownership of more than fifty (50%) percent of the voting stock of any organization or the legal power to direct or cause the direction
of the general management of the organization as appropriate, and “Controlled” shall be construed accordingly.

 

		1.3	“Agreed Hourly Rate” means the hourly rate which has
been agreed between both Parties as per Schedule 1.

 

    1

     

    

 

		1.4	“Applicable Laws” means the applicable provisions of
constitutions, statutes, laws, rules, treaties, regulations, orders and decrees of all applicable Regulatory Authorities.

 

		1.5	“Batch” means a batch of the Product manufactured by
Manufacturer on a [***] litre scale under cGMP, in accordance with the Services Related Requirements of the Specifications and Quality
Agreement and using the Manufacturing Process.

 

		1.6	“Batch Documentation” means all documentation relating
to a Batch, including the executed Batch record and additional documents relating to the Batch such as the analytical testing records,
the release for the Materials, deviations, and all documents relating to a Batch that Manufacturer is required to maintain according to
cGMP, the Services Related Requirements of the Specifications, the Quality Agreement, the relevant Purchase Order or Work Order, and all
Applicable Laws.

 

		1.7	“Change of Control” means with respect to Manufacturer,
the consummation of any transaction (or series of related transactions) of the following events: (a) any Third Party (or group of Third
Parties acting in concert) becomes the beneficial owner, directly or indirectly, of more than fifty percent (50%) of the total voting
power of the stock or other ownership interests (as applicable) then outstanding of Manufacturer normally entitled to vote in elections
of directors or equivalent governing body, (b) Manufacturer consolidates with or merges into another entity, or any entity consolidates
with or merges into Manufacturer, in either event pursuant to a transaction in which more than fifty percent (50%) of the total voting
power of the stock or other ownership interests (as applicable) outstanding of the surviving entity normally entitled to vote in elections
of directors or equivalent governing body is not held by the parties holding at least fifty percent (50%) of the outstanding stock or
other ownership interests (as applicable) of Manufacturer immediately preceding such consolidation or merger, (c) any other arrangement
whereby a Third Party controls or has the right to control the board of directors or equivalent governing body that has the ability to
cause the direction of the management or policies of Manufacturer or (d) Manufacturer shall dissolve, transfer, sell, assign, mortgage,
encumber, pledge, or otherwise dispose of (i) all or substantially all of its assets, or (ii) any controlling interest in its business
(whether in the form of stock or otherwise) or the Manufacturing Site.

 

		1.8	“Commercial Manufacturing Services” means the tasks and
activities to be performed by Manufacturer hereunder, except for the Development Services, as further set out in the Agreement and in
the Purchase Orders, in case all conditions under Section 2.2 are met and satisfied, which shall include, (i) the manufacture of (Batches
of) the Product using the Manufacturing Process, (ii) all activities and services (be it under cGMP, research laboratory or non-cGMP conditions)
related thereto, such as, without limitation, performance of assays and other analytical work, quality control of the Product, storage
of the Product, and (iii), storage activities, and (iv) all further services and activities (be it under cGMP, research laboratory or
non-cGMP conditions) as may be mutually agreed in writing between the Parties from time to time; all as performed by the Manufacturer
011 behalf of Merck pursuant to the terms and conditions of this Agreement. For the avoidance of doubt, Manufacturing Services do not
include tasks and activities to be performed by Merck (such as sample analysis) and Manufacturer shall not be liable hereunder for any
failure of Merck in performing such tasks and activities.

 

		1.9	“Commercially Reasonable Efforts” means, with respect
to the efforts to be expended by either Party with respect to any objective, such reasonable, diligent, and good faith efforts as such
Party would normally use to accomplish a similar objective under similar circumstances as expeditiously as possible, which in no event
shall be less than the standard of care generally adhered to in the industry of such Party for the providing of such efforts. “Confidential
Information” means any and all information (in whatever form, tangible or intangible) relating to either Party’s, their
Affiliates’ and/or their business partners’ business and/or technologies and/or any business, employee or customer information
or data which is disclosed, or otherwise comes into possession of the other Party, directly or indirectly as a result of this Agreement
and which is of a confidential nature (including, without limitation, any information relating to business affairs, operations, products,
processes, methodologies, formulae, plans, intentions, projections, know-how, Intellectual Property, trade secrets, market opportunities,
suppliers, customers, marketing activities, sales, software, computer and telecommunications systems, costs and prices, wage rates, records,
finances and personnel).

 

    2

     

    

 

		1.10	“Confidentiality Agreement (CDA)” means the confidentiality
agreement entered into between the Parties effective as of [***].

 

		1.11	“Current Good Manufacturing Practice” or “cGMP”
means the Current Good Manufacturing Practices officially published and interpreted by EMA, FDA and other applicable Regulatory Authorities
that may be in effect from time to time and are applicable to the Manufacture of the Product(s) in the Territory, as required:

 

		(A)	if the Manufacturing Site is within the European Union or if the Product(s) is/are to be supplied to a
country within the European Union, by the standards, rules, principles and guidelines set out in the provisions of Chapter II of EC Commission
Directive 2003/94/EC, together with Volume 4 of the Rules Governing Medicinal Products in the European Union entitled “EU Guidelines
to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use”;

 

		(B)	if the Manufacturing Site is within the United States of America, or if the Product(s) is/are to be supplied
to the Unites States of America, by the provisions of 21 C.F.R., parts 210 and 211 and all applicable rules, regulations, orders and guidance
published by the FDA (as defined below);

 

		(C)	if the Manufacturing Site is in, or if the Product(s) is/are to be supplied to, any other part of the
Territory, such standards as the Parties may agree in writing to reflect the requirements of Regulatory Authorities in the country of
manufacture or supply; and

 

		(D)	such other requirements as agreed between the Parties and set out in the Quality Agreement, in each case,
as amended and updated from time to time.

 

		1.12	“Defect” means, in respect of a Product, a failure to
comply with the applicable Specification and/or to have been manufactured in accordance with cGMP, and “Defective”
shall be construed accordingly.

 

		1.13	“Defective Product” means a Product with a Defect.

 

		1.14	“Delivery Date” means the date agreed by Merck and Manufacturer
for the delivery of Products in a Work Order or in a Purchase Order according to ARTICLE 4.

 

		1.15	“Delivery Terms” means EXW [***] Incoterms 2010 or such
other terms as may be agreed in writing between the Parties and terms such as “delivery” and “delivered” shall
be construed accordingly. Accordingly, Merck shall be responsible for the transport of the Product and shall engage a carrier. However,
Manufacturer shall coordinate in advance with Merck’s carrier each shipment of the Products.

 

    3

     

    

 

		1.16	“Development Services” means all the tasks and activities
to be performed by Manufacturer pursuant to Schedule 5 for the supply of the Product in the context of the phase III clinical trial
described in the recitals above including but not limited to the Technical Transfer, the manufacture and supply of Engineering Batche(s),
the GMP Batches (Phase III) and the PPQ Batches, as described in Schedule 5. In the event Merck reasonably requires further tasks
and activities for the manufacture of the Product to be used by Merck for development purposes in a phase III clinical trial and Manufacturer
is able to provide such further tasks and actives, Manufacturer shall upon request of Merck provide them against Merck’s payment
of a reasonable additional price.

 

		1.17	“Engineering Batch” means a Batch that is produced to
test production equipment, to finalize process control strategy and/or to train operations staff and is not released by Manufacturer for
human use. Engineering Batches to test the production equipment will be produced at the Manufacturing Site. Engineering Batch will be
at the cause scale as [***].

 

		1.18	“Executive Officers” means, together, a member of the
senior management of the pharmaceutical division of Merck /executive management board of the pharmaceutical division reporting to the
executive board of Merck and the Chief Executive Officer of Manufacturer.

 

		1.19	“Finished Medicinal Product” means any pharmaceutical
product(s) comprising the Product.

 

		1.20	“Force Majeure Event” means in relation to either Party,
any circumstances beyond the reasonable control (including the taking of reasonable precautions) of that Party (including without limitation
any acts or restraints of governments or public authorities, war, terrorism, revolution, riot or civil commotion disruption at suppliers,
fire, explosion, accident, flood, sabotage, lack of adequate fuel, power, Materials, transportation, labour dispute and/or general strike
of a national or industry-wide nature).

 

		1.21	“Governmental Authority” means any court, tribunal, arbitrator,
agency, legislative body, commission, official or other instrumentality of (i) any government of any country, (ii) a federal, state, province,
county, city or other political subdivision thereof or (iii) any supranational body, including any Regulatory Authority.

 

		1.22	“Hazardous Materials” means any material or substance
that, whether by its nature or use, is now or hereafter defined or regulated as a hazardous waste, hazardous substance, pollutant, or
contaminant under any Applicable Law relating to or addressing public and employee health and safety and protection of the environment,
or which is toxic, explosive, corrosive, flammable, radioactive, carcinogenic, mutagenic or otherwise hazardous or which is or contains
petroleum, gasoline, diesel, fuel, another petroleum hydrocarbon product, or polychlorinated biphenyls. Hazardous Materials specifically
include asbestos-containing materials (ACM), mold and lead-based paints.

 

		1.23	“Independent Expert” means a laboratory or expert mutually
agreed upon by the Parties who shall act as an expert in accordance with the ICC Rules for Expertise, and if no agreement can be reached
then the Parties will accept a laboratory or expert appointed by the International Chamber of Commerce of Switzerland according to the
ICC Rules for Expertise.

 

		1.24	“Intellectual Property” means patents, trademarks, service
marks, design rights (whether registerable or otherwise), including applications for any of the foregoing, copyright, all rights in know-how,
trade or business secrets and/or trade or business names and other rights or forms of protection of a similar nature or having equivalent
or similar effect to any of these which may subsist anywhere in the Territory whether registerable or not.

 

    4

     

    

 

		1.25	“Latent Defect” means a Defect existing at the time of
delivery of the Product in question to Merck, but which could not reasonably be discovered by a visual inspection of its outer packaging
or any accompanying documentation.

 

		1.26	“Losses” means all losses, claims, liabilities, costs,
awards, fines, penalties, expenses (including reasonable attorney’s fees, court fees and other reasonable professional expenses)
and damages of any nature whatsoever reasonably foreseeable and unavoidable, however, always excluding any loss of profit or anticipated
profit, loss of production, losses caused by business interruptions, loss of revenue and loss of goodwill or reputation.

 

		1.27	“Manufacturing License” means any consent, permit, authorization
or approval required for or in connection with the Manufacture of the Product at the Manufacturing Site(s)and the export/import of the
Product to Merck in accordance with the Delivery Terms, including any license required pursuant to Article 13.1 of the Directive 2001/20/EC,
Article 61 of Regulation 536/2004, Article 40 of Directive 2001/83/EC and, as applicable, a current drug establishment registration
with the FDA (as defined below) as set forth in 21 C.F.R. §207.

 

		1.28	“Manufacturing Process” means the anti IL-17 A/F Nanobody
manufacturing process proprietary to Merck and transferred to Manufacturer as set out in the master batch records of the Product.

 

		1.29	“Manufacturing Run” means a manufacturing run for the
Product on a [***] scale under cGMP, in accordance with the Services Related Requirements of the Specifications and Quality Agreement
and using the Manufacturing Process.

 

		1.30	“Manufacturing Site” means the manufacturing facility
located at [***] or such other manufacturing facility of Manufacturer as agreed to by the Parties pursuant to the change control procedures
set out in the Quality Agreement.

 

		1.31	“Materials” means the active ingredients, raw materials,
excipients, packaging materials and components used in the manufacture of the Products.

 

		1.32	“Price” means for Development Services the amounts set
out in Schedule 1 and for Commercial Manufacturing Services, the price set out in Section 6.2.

 

		1.33	“Product License” means the product license, marketing
authorization or any other authorization(s) (as the case may be) required for the marketing, sale and/or distribution or clinical investigation
of Finished Medicinal Products by Merck in the jurisdictions in which the foregoing activities take place, or extension or renewal of
any of the foregoing.

 

		1.34	“Product(s)” means each of the products set out in the
Specifications as included in the Quality Agreement.

 

		1.35	“Qualified Person” means the person named in the Quality
Agreement (or any replacement notified in writing by Manufacturer, from time to time), who is suitably qualified to enable Manufacturer
to perform and discharge its quality management obligations as required by Current Good Manufacturing Practice or other Applicable Laws.

 

    5

     

    

 

		1.36	“Quality Agreement” means the future document outlining
the Parties’ respective responsibilities on quality matters, as the same may be amended by written agreement between the Parties.

 

		1.37	“Quality Control Procedure” means the analytical testing
of a Batch according to written testing instruction including in-process-control testing and analytical testing of the Product.

 

		1.38	“Regulatory Authority” means any multinational, federal,
state, local, municipal or other Governmental Authority in the Territory having jurisdiction over any aspect of the activities contemplated
by this Agreement, including to the extent applicable, in the United States, the United States Food and Drug Administration (“FDA”),
and in the European Union, the European Medicines Agency.

 

		1.39	“Services” means Development Services and Commercial
Manufacturing Services.

 

		1.40	“Services Related Requirements” means all provisions
of the Specifications which describe or require a certain minimum conduct and/or level of performance of Manufacturer when performing
a Service as further described in this Agreement and the Quality Agreement as opposed to “Product Related Requirements”
which describe a certain measurable property of a deliverable (such as impurities allowed in the Product) resulting from Manufacturer’s
performance of a Service.

 

		1.41	“Specifications” means with respect to each Product the
technical specifications for the required quality and characteristics of the Product agreed between the Parties in writing in the Quality
Agreement (as the same may be amended from time to time in accordance with this Agreement).

 

		1.42	“Steering Committee” means within thirty (30) days alter
the Effective Date, the Parties will establish a joint steering committee to oversee and manage the Parties activities under this Agreement.
The Steering Committee will continue to be in effect throughout the Term of the Agreement and will disband following termination of the
Agreement.

 

		1.43	“Territory” means as of the Effective Date any country
of the European Union and the United States of America. Merck shall be entitled to include further countries into the Territory including,
without limitation, China and Japan by written notice to Manufacturer provided (a) Manufacturer, acting reasonably, is able to fulfil
any additional regulatory or other requirements of any such further country, and (b) Merck agrees to bear all additional costs of Manufacturer
arising from the inclusion of any such further country.

 

		1.44	“Third Party” means any person or entity other than a
Merck or Manufacturer or their Affiliates or [***] or any other third party having signed an agreement with Merck in relation to the Trial.

 

		1.45	“Trial” means the Phase III clinical trial of the Product
conducted or sponsored by Merck or a Merck’s designated third party described in the recitals above.

 

		1.46	“Trial Authorizations” means all regulatory and ethical
authorizations and approvals required for the lawful conduct of the Trial by Merck or by a Merck’s designated third party.

 

		1.47	“Trial Subject” means an individual enrolled into the
Trial in accordance with the Protocol.

 

		1.48	“Work Order” means Merck’s order for Manufacturing
Runs which are part of the Development Services.

 

    6

     

    

 

		1.49	“Working Day” means a day other than Saturday or Sunday
or a day that is a public holiday in the jurisdiction in which the Manufacturing Site is located.

 

		1.50	Other Terms. The definition of each of the following terms is set
forth in the section of the Agreement indicated below:

 

	
    Defined Term
	Section
	Acceptance	9.3
	Average Yield	5.11
	Background IP	3.1
	BCP	21
	Consequential damages	18.3
	Designated Vendors	2.10(a)
	Effective Date	Preamble
	FDA	1.38
	Firm Zone	4.2
	Green Zone	4.2
	Initial Term	19.1
	KPIs	5.9
	Manufacturer Background IP	3.1
	Manufacturer Confidential Information	16.8
	Manufacturing Problem	5.7
	Manufacturing Problem Notice	5.8
	Merck Arising IP	3.2
	Merck Background IP	3.1
	Non-Escalable Dispute	22.1
	Payee	6.19
	Payer	6.19
	Payments	6.19
	Product Event	15.1
	Purchase Order	4.5
	Punitive Damages	18.3
	REACH	13.11
	Renewal Term	19.1
	Required Manufacturing Change	12.3
	Rolling Forecast	4.1
	Taxes	6.18
	Technical Change	12.1
	Term	19.1
	Third Party Claims	18.1
	Yearly Capacity Reservation	2.6

 

    7

     

    

 

Article
2

MANUFACTURER’S OBLIGATIONS

 

		2.1	Scope of the Agreement. Manufacturer agrees to provide Merck with
both Development Services and Commercial Manufacturing Services including the manufacture and sale to Merck of Products ordered by Merck
in accordance with ARTICLE 4 in consideration of Merck paying the Price for the Services.

 

		2.2	Notwithstanding the execution of this Agreement, the commencement of certain
Services described herein below is subject to and conditional an satisfaction or waiver by Merck of the following conditions:

 

		i	For the start and continuation of GMP manufacturing of at least [***] [***] Batches : (i) the Manufacturer
has transferred the process from Merck to his relevant site(s) without any major deviation from the agreed timelines underProject Timelines
and the Product Specifications, and (ii) the Parties have signed the Quality Agreement.

 

		ii	For the start of the manufacturing of at least [***] [***] Batches: the Manufacturer has successfully
supplied Merck with at least [***] [***] Batches without any major deviation from the Project Timelines and according to the Product Specifications

 

		iii	For the start of the Commercial Manufacturing Services: (i) Manufacturer shall have successfully manufactured
and supplied to Merck at least [***] [***] Batches without any major deviation from the Project Timelines and according to the Product
Specifications, (ii) Merck Phase III Clinical Trials data package can support a successful BLA registration and (iii) Merck has decided
to go on with the commercial manufacturing of the Products.

 

For the purpose of this Section 2.2 a
major deviation from the Project Timelines herein consists of a delay from such Project Timelines equal to or longer than [***].

 

		2.3	In case one of the conditions under Section 2.2 is not met, Merck shall
have the right to terminate the Agreement in accordance with Section 19.2.

 

		2.4	No General Terms and Conditions. The supply of the Product shall
be exclusively governed by the terms and conditions of this Agreement. General terms and conditions of the Parties shall not apply even
if mentioned by routine in a Work Order or Purchase Order of Merck or in any of Manufacturer’s order confirmations.

 

		2.5	Project Timelines. Manufacturer will provide Merck with the Services
within the Project Timelines indicated in Schedule 5 (“Project Timelines”). Table 1 of Schedule 5 indicates
some binding timelines to be complied with by Manufacturer and Table 2 of Schedule 5 indicates some indicative timelines, which
will be further discussed and agreed upon by the Parties. In case Manufacturer does not comply with a binding Project Timeline or does
not use Commercially Reasonable Efforts to comply with an agreed indicative timeline, Merck, without prejudice to Sections 9.8 and 9.9
as applicable, may either request the payment of a late performance penalty in accordance with Section 5.6 (where applicable) and/or terminate
this Agreement in accordance with ARTICLE 19.

 

		2.6	Capacity Reservation of Products in the performance of Commercial Manufacturing
Services. Following Manufacturer’s letters to Merck dated [***] and [***] about capacity expansions (attached in Schedule
7), in view of performing the Commercial Manufacturing Services Manufacturer hereby commits on a yearly capacity reservation (“Yearly
Capacity Reservation”) as shown in the table below. Such reservation shall terminate automatically in case Merck does not place
Purchase Orders with the Manufacturer, observing the agreed lead time. Unless otherwise agreed, the Yearly Capacity Reservation from [***]
onwards shall be of [***] Manufacturing Runs. In case Manufacturer foresees that it will not be able to fulfil the below Yearly Capacity
Reservation, Manufacturer shall send to Merck a written notice at least [***] in advance. In this event, Manufacturer shall bear the technology
transfer costs of the transfer of the Manufacturing of the Products to another manufacturer.

 

	
     

    Year
	2022	2023	2024	2025
	Yearly Capacity Reservation ([***])	[***]*	[***]*	[***]*	[***]*

 

		*	The specific number of reserved Manufacturing Runs at [***] scale will be defined according to the
                                                                                Rolling Forecasts provided by Merck.

 

    8

     

    

 

		2.7	Expansion of the Manufacturing Capacities. In order to meet a potential
increase of Product demand by Merck from [***] Manufacturing Run in [***] to the [***] Manufacturing Runs from [***] onwards as shown
in the table under Section 2.6, Manufacturer undertakes to expand at its own cost its manufacturing capacity accordingly in [***]. In
the event Merck requires more than [***] and up to [***] Manufacturing Runs, Manufacturer shall set up a fully dedicated line for Merck.
In such case, Merck shall inform Manufacturer at least [***] in advance of its additional Product requirements to allow Manufacturer to
plan the investment and discuss necessary changes to this Agreement which may then include annual minimum order quantities in order to
ensure utilization of the dedicated line.

 

		2.8	Restrictions on Competing Products. During the Term, Manufacturer
shall not manufacture on its own or for any Third Party or engage in the performance of services for a product which competes with the
Product in the [***].

 

		2.9	Standards Applicable to the Manufacture of the Product. Manufacturer
shall manufacture the Products at the Manufacturing Site in accordance with Current Good Manufacturing Practice, the Specifications, the
Manufacturing License, the Quality Agreement, Merck’s Labelling and all Applicable Laws relevant to the Manufacture of the Products
and with personnel that are knowledgeable, qualified and trained to perform the activities required to Manufacture the Products in accordance
with the terms and conditions of this Agreement.

 

		2.10	Designated Vendors

 

		(a)	Approval of Designated Vendors. If Merck elects, at its sole discretion, to require Manufacturer
to procure Materials from Third Parties designated and approved by Merck in writing (“Designated Vendors”) which are
not then under contract with Manufacturer, Merck shall so advise Manufacturer in writing, and Manufacturer shall establish supply arrangements
with such Designated Vendors (which supply arrangements shall comply with the terms of this Agreement, the Quality Agreement and any other
related agreements) and the terms and conditions of such supply shall be subject to the approval of Merck. If Merck elects that Materials
need to be purchased by vendors which are not qualified vendors of Manufacturer, Merck shall bear the cost for contracting, qualification
and auditing of those vendors. Manufacturer shall allow Merck to agree with Designated Vendors an indemnification of Merck and Manufacturer
by such Designated Vendors with respect to risks or liabilities created by such Designated Vendors, and include Merck as a Third Party
beneficiary of these provisions. Manufacturer has to qualify such Designated Vendors according to cGMP requirements and establish the
related contractual framework (including a Quality Agreement) also to support the terms of this Agreement and ancillary agreements hereto.

 

		(b)	Notification. Manufacturer shall immediately advise Merck if it encounters supply problems, including
delays and/or delivery of non-conforming Materials from Designated Vendors and (except to the extent Materials are provided by Merck)
Manufacturer shall use Commercially Reasonable Efforts to reduce and eliminate any supply problems from such Designated Vendors (and Merck
shall provide Manufacturer with reasonable assistance in connection therewith).

 

		(c)	Audits and Assessment. Manufacturer shall maintain an adequate system, which functions as a risk-based
assessment of Designated Vendors that provide Materials to ensure compliance with the terms of this Agreement and any ancillary agreements
hereto, cGMPs and Applicable Laws. Furthermore, Merck may, at its option, independently conduct audits or participate in Manufacturer
audits (including, but not limited to, quality, safety, social responsibility and environment) of such Designated Vendors, on a routine
or for-cause basis. As a result of such audits, if necessary, Merck shall have the right to direct Manufacturer to disqualify a Designated
Vendor as a source of Materials. Manufacturer shall use Commercially Reasonable Efforts to identify a new supplier as a source of Materials
and replace the disqualified supplier with such new supplier, pursuant to the provisions set forth in Section 2.10 (a) above at Merck’s
expense.

 

    9

     

    

 

		2.11	Use of Affiliates and Subcontractors. Manufacturer may not, without
the prior written consent of Merck, use Affiliates or Third Party sub-contractors to perform the Services. For any subcontract authorized
by Merck, Manufacturer shall ensure that the subcontractor complies with the obligations and restrictions applicable to Manufacturer under
this Agreement and shall further ensure that its subcontractor protects Merck’s interests in Confidential Information, Merck Background
IP and Merck Arising IP. Manufacturer (a) shall manage the performance of the subcontractor at its sole cost and expense and (b) shall
remain responsible to Merck for all acts and omissions of any subcontractor and the performance of those subcontracted activities just
as though Manufacturer had performed them itself and for purposes of this Agreement such acts or omissions and the performance of those
subcontracted Services shall be deemed to be Manufacturer’s. Manufacturer shall be Merck’s sole point of contact regarding
the Services, including with respect to payment. Merck hereby agrees that the external [***] services will be provided by the service
providers listed in the Quality Agreement, being Manufacturer’s sole subcontractor as of the Effective Date. For the avoidance of
doubt, the costs for any external [***] services are not included in the Price for the Product and will be passed on to Merck plus a [***]
handling fee.

 

		2.12	Responsibility. Unless otherwise specified herein or expressly consented
to in writing by Merck, as between the Parties, Manufacturer shall be solely responsible for performance of all Services necessary for
Merck to be supplied with Products as agreed hereunder including the ordering and purchasing all of the Materials to enable Manufacturer
to meet its manufacturing and delivery obligations under this Agreement.

 

		2.13	Safety Stock. During the Term, Manufacturer shall maintain at all
times a safety stock of Materials (list of Materials to be agreed in writing between the Parties) sufficient to meet the Manufacturing
Runs set out in the Firm Zone, unless mutually agreed to in writing by Merck Manufacturer shall notify Merck immediately whenever the
inventories of Materials become insufficient to Manufacture enough Product to meet the Manufacturing Runs set out in the Firm Zone. Manufacturer
will pay the Materials. However, all Materials will then be invoiced by Manufacturer to Merck upon their receipt. Manufacturer shall send
to Merck an invoice with a copy of the invoice paid by Manufacturer for the Materials. Merck shall pay this invoice within [***] after
its receipt.

 

		2.14	Development Services

 

		(a)	Performance. Manufacturer shall perform the Development Services set out in Schedule 5 to
this Agreement pursuant to and consistent with the terms of this Agreement, any applicable Specifications and Schedule 5, all reasonable
written directions and instructions from Merck, generally accepted professional standards of care and all Applicable Laws of each country
where Development Services shall be conducted, including without limitation cGMPs. Manufacturer shall perform all Development Services
in a competent, professional and in a timely manner. Manufacturer shall perform all quality reviews, quality controls and process checks
necessary in their performance of Development Services and as outlined in Schedule 5 in accordance with the quality standards agreed
upon by Merck and Manufacturer in Schedule 5 and the Quality Agreement.

 

    10

     

    

 

		(b)	Purchaser Obligations. Merck shall provide to Manufacturer (in a timely manner) such assistance,
information and co-operation as reasonably requested by Manufacturer in connection with the performance of the Development Services.

 

		(c)	Change Orders. Merck may, from time to time, submit to Manufacturer a request for changes to Schedule
5. Unless, in Manufacturer’s reasonable judgment, Manufacturer can implement the requested changes without requiring additional
Manufacturer time or resources and without affecting Manufacturer’s ability to maintain the Project Timeline, Manufacturer will
implement the change at Merck’s expense. Manufacturer will provide Merck with a written change order proposal for the additional
work, including: (i) price change, (ii) impact an Project Timelines, and (iii) revised Schedule 5, including additional requirements
of Merck, if any. Merck may, at its discretion, accept or reject Manufacturer’s change order proposal. Each Party will use Commercially
Reasonable Efforts to respond as expeditiously as possible to change order proposals.

 

		(d)	Work Location. Manufacturer shall perform the Development Services to be provided under this Agreement
at the location indicated in Schedule 5, or, if no such location is indicated, at the Manufacturing Site unless mutual agreement
to the contrary has been made and stipulated by the Parties.

 

		(e)	Project Staffing. Manufacturer shall perform the Development Services with highly qualified, trained
and educated personnel knowledgeable and trained as appropriate for a particular Development Service in cGMPs, applicable regulatory requirements,
fraudulent practices, project management, and pharmaceutical drug development and related services. Manufacturer is responsible for the
training of its staff in order to maintain their knowledge to the standards of the industry and to perform their obligations under this
Agreement and Schedule 5. All costs and expenses for such training will be fully paid by Manufacturer.

 

Article
3

INTELLECTUAL PROPERTY

 

		3.1	Background IP. Each Party shall, at all times throughout and after
the Term, remain the owner of any and all Intellectual Property that it owned (or was licensed to use) by the effective date of the signed
CDA, and which Intellectual Property shall, for the purposes of this Agreement, be defined as “Background IP”. Manufacturer
acknowledges that Intellectual Property relating to the Products shall remain vested solely and exclusively in Merck or its relevant Affiliate.
Merck acknowledges that Intellectual Property relating to manufacturing processes, including testing and packaging, which are generally
used at the Manufacturing Site (to the extent existing prior to the Effective Date, or developed independently of this Agreement without
the use of Merck’s Confidential Information), shall remain vested in Manufacturer or its relevant Affiliate. For the purposes of
this Section, Background IP vested in Merck (or its Affiliates) shall be defined as “Merck Background IP” and Background
IP vested in Manufacturer (or its Affiliates) shall be defined as “Manufacturer Background IP”.

 

		3.2	Merck Arising IP. Neither Manufacturer, its Affiliates, nor any of
their respective subcontractors shall acquire any rights of any kind whatsoever with respect to the Products by conducting Manufacturing
activities hereunder. All rights to any Intellectual Property (whether or not patentable) conceived (whether or not reduced to practice)
in the performance of work conducted under this Agreement by Manufacturer’s or its Affiliates’ employees, or independent contractors,
either solely or jointly with employees, agents, consultants or other representatives of Merck exclusively or primarily relating to the
Products or the manufacturing, processing, testing, packaging, storing thereto, will be owned solely and exclusively by Merck (“Merck
Arising IP”).

 

    11

     

    

 

		3.3	Use of Intellectual Property. Manufacturer will not use, or allow
others to use, any Merck Background IP or Merck Arising IP for any other purpose than the Manufacture of the Products for Merck. Merck
hereby grants Manufacturer and any Affiliates and subcontractors approved by Merck a non-exclusive and royalty free license for the Term
to use the Merck Background IP and Merck Arising IP to the extent necessary to Manufacture the Products under this Agreement. Manufacturer
hereby grants Merck and its Affiliates an irrevocable, worldwide, non-exclusive, and royalty free license to use the Manufacturer Background
IP to the extent necessary for Merck or its Affiliates to further manufacture, commercialize, distribute, market, export, sell and otherwise
exploit the Products.

 

		3.4	Assistance. Manufacturer shall fully cooperate in the preparation,
filing, prosecution and maintenance of all trademarks, copyrights, patents or other intellectual Property of any Merck Arising IP at Merck’s
cost and expense. Such cooperation shall include execution of all papers and instruments appropriate so as to enable Merck to prepare,
file, prosecute and maintain such rights in any country.

 

Article
4

FORECASTS AND ORDERS

 

		4.1	Forecast. Provided that all conditions under Section 2.2 have been
met, in view of the performance by Manufacturer of the Commercial Manufacturing Services Merck shall provide a rolling forecast for [***]
(the “Rolling Forecast” or “RF”). The RF shall be updated on a [***] basis and shall be delivered
by Merck to Manufacturer by [***] of each [***]. The minimum order size will be [***] Batches per campaign and the maximum order size
will be [***] Batches per [***], i.e. a Purchase Order for one (1) campaign consisting of [***] needs to be spread over [***].

 

		4.2	The first [***] of the RF (e.g. [***] to [***] of the following [***] in
a RF provided on [***]) shall be broken down on a [***] basis. The first [***] thereof shall be firm and cannot be changed (“Firm
Zone”). The [***] of the RF shall constitute a non-binding forecast (“Green Zone”), however, the first [***]
of the Green Zone may only be changed [***], i.e. the number of Manufacturing Runs forecasted for the first [***] of the Green Zone cannot
be [***] without prior agreement between the parties.

 

		4.3	On or before [***] after receipt of the RF by Manufacturer, Manufacturer
shall inform Merck in writing if it is able to fulfil such RF, whether related to the Firm Zone or Green Zone as depicted. If no notification
is received by Merck within that [***] period then the RF shall be deemed to have been accepted by Manufacturer, unless such RF exceeds
the Yearly Capacity Reservation. Upon agreement of a RF Manufacturer shall submit to Merck on or before [***] a plan for Product delivery
and tentative production schedule for the [***] of the RF. During the RF negotiations, the Parties shall also discuss any implications
with regard to the residual shelf life of Product to be delivered under such RF.

 

		4.4	In the event the Manufacturer cannot fulfil any part of a RF relating to
the Green Zone, then the Parties shall discuss and agree on quantities and delivery dates of Product which are mutually acceptable. Manufacturer
shall be obliged to supply Merck with commercial supply of the Product in accordance with the agreed upon RF.

 

    12

     

    

 

		4.5	Orders of Manufacturing Runs for commercial purposes - Purchase Orders.
Provided that all the conditions precedents under Section 2.2 are met and the Commercial Manufacturing Services start, Merck shall throughout
the Term, order Manufacturing Runs by delivering purchase orders to Manufacturer (each such order being referred to as a “Purchase
Order”). Each Purchase Order shall, unless otherwise agreed between the Parties, specify the number of Manufacturing Runs ordered
and the required Delivery Date which shall be at least [***] after the date of receipt of the Purchase Order by Manufacturer. Unless otherwise
agreed, Merck’s Purchase Order must allow for a Manufacturing in maximum [***] campaigns per calendar year.

 

		4.6	Manufacturer’s Response to Purchase Orders. Purchase Orders
under Section 4.5 above shall be issued by Merck either electronically or by such other means, and to such location or contact person
or system, as Manufacturer shall specify in writing. Manufacturer shall respond to each such Purchase Order received from Merck within
[***] from receipt. Provided that (i) the number of Manufacturing Runs ordered by Merck does not exceed the number of Manufacturing Runs
forecasted for the respective [***] in accordance with Sections 4.1 and 4.2 above, (ii) the Purchase Order allows for a Manufacturing
in maximum [***] per [***], (iii) Merck complies with the above lead time of [***] under Section 4.5 and (iv) Merck’s Purchase Order
otherwise complies with this Agreement, Manufacturer shall accept the Purchase Order and its response shall include confirmation of the
number of Manufacturing Runs and the Delivery Date. Deliveries confirmed by Manufacturer shall not occur later than [***] from the date
indicated in the relevant Purchase Order. A failure of Merck to issue a Purchase Order shall not affect Merck’s obligations to purchase
the quantities set forth in the Firm Zone and, accordingly, in the event of any such failure, the missing Purchase Order shall be deemed
issued by Merck. For the avoidance of doubts, in the event Merck cancels a Purchase Order issued or deemed issued within the Firm Zone,
Merck shall pay [***] of the Price of each cancelled Purchase Order.

 

		4.7	Orders of Manufacturing Runs during the development phase - Cancellation
of Work Orders. In the context of the Development Services Merck shall order the Manufacturing Runs by issuing specific Work Orders
to Manufacturer. Each Work Order shall, unless otherwise agreed between the Parties, specify the number of Manufacturing Runs ordered
and the required Delivery Date reflecting the timeline under Schedule 5. Each Work Order shall be issued and sent to Manufacturer
at least [***] prior the Delivery Date of the Manufacturing Runs indicated in such Work Order except for the Work Order for the first
[***] Batch for which the Work Order shall be issued and sent to the Manufacturer at least [***] prior to Delivery Date. Provided that
Work Orders are in line with the number of Batches agreed under Section 2.2 (i) and (ii) the timelines set forth in Schedule 5,
Work Orders issued by Merck under this Section 4.7 at least [***] prior the Delivery Date of the Manufacturing Runs indicated in such
Work Order shall be accepted the Manufacturer within [***] from the receipt of the Work Order.

 

		4.8	Merck may cancel a Work Order without any obligation or incurring any liability
to manufacture at the latest [***] prior to the Delivery Date. If notice of the cancellation or reduction is given by Merck less than
[***] prior to the Delivery Date, Merck shall be obliged to make the following payment to Manufacturer:

 

		(a)	If notice is given by Merck between [***] and [***] prior to the Delivery Date, Merck shall pay [***]
of the Price for each cancelled Manufacturing Run except if these can be used for further campaigns (if the shelf life allows it).

 

		(b)	If notice is given by Merck between [***] to [***] prior to the Delivery Date, Merck shall pay [***] of
the Price of each cancelled Manufacturing Run.

 

    13

     

    

 

		(c)	If notice is given by Merck less than [***] prior to the Delivery Date, Merck shall pay [***] of the Price
for each cancelled Manufacturing Run.

 

		4.9	Reallocation of Manufacturing Runs in case of cancellation of Purchase
Orders and Work Orders. Manufacturer shall use Commercially Reasonable Efforts to re-allocate the manufacturing slot for any such
cancelled Manufacturing Run (whether set out in a Work Order or Purchase Order) to customers of Manufacturer for non GMP or GMP Batches,
and/or shall consider in good faith a proposal of an alternative project or use for the manufacturing slot by Merck and/or its Affiliates;
and if Manufacturer successfully re-allocates the manufacturing slot, Merck shall not be required to make any of the payments above but
only for Materials purchased for the cancelled Manufacturing Run which cannot be used for a later Manufacturing Run as well as for any
other non-cancellable costs of Manufacturer.

 

		4.10	Addressees for Correspondence. All Forecast Schedules, Purchase or
Work Orders, written confirmation of Purchase or Work Orders and other notices contemplated under this ARTICLE 4 shall be sent to the
attention of such Party as set forth in Section 23.10, or such persons as each Party may identify to the other in writing from time to
time.

 

		4.11	Affiliates of Merck. Affiliates of Merck may order Products directly
from Manufacturer. Manufacturer shall manufacture and supply to such Affiliates the ordered Products in accordance with the terms and
conditions of this Agreement.

 

Article
5

DELIVERY OF PRODUCT

 

		5.1	Delivery. Manufacturer shall provide Merck with authorized electronic
copies of the [***] records, the [***], the [***], and when applicable, the [***] at each time point and the invoice for each Manufacturing
Run in accordance with the Delivery Terms on the Delivery Date specified in the relevant Work Order or Purchase Order confirmed by Manufacturer
pursuant to ARTICLE 4 above. For the avoidance of doubt, punctual “delivery” in terms of this Agreement by Manufacturer does
not require the pick-up of the stored Product by Merck but shall occur upon Manufacturer providing the above mentioned documents to Merck.
As defined in Section 7.2, in case Manufacturer will store Product [***] at Merck’s demand at Manufacturer’s premises, payment
process will be triggered at the reception of the Batch Documentation.

 

		5.2	Sample Analysis by Merck. Delivery dates set out in a Work Order
or Purchase Order include [***] for the results (starting from samples arrival at the site in [***] designated by Merck for the performance
of the samples analysis) of the sample analysis performed by Merck in accordance with the Manufacturing Process. Any delay of Merck may
lead to a potentially much longer delay of the delivery of the respective Batch, in particular if Merck misses the slot reserved at Manufacturer
for the final review of the Batch Documentation. Manufacturer shall not be responsible for any delay caused by Merck failure to perform
sample analysis within [***]. Upon Merck’s notice that sample analysis may be delayed by a certain number of days or weeks, Manufacturer
shall inform Merck whether and, if so, to what delay of the delivery of the respective Batch this will lead. If a slot for the final review
of the Batch Documentation at Manufacturer is missed due to Merck’s delay, Manufacturer shall use the next free slot.

 

		5.3	Title; Risk of Loss. Risk and title in the Products shall remain
with Manufacturer until delivered in accordance with the Delivery Terms at which point it shall pass to Merck.

 

    14

     

    

 

		5.4	Accompanying Documentation. With each shipment of Product, Manufacturer
shall provide Merck with the documentation set forth in the Quality Agreement.

 

		5.5	Retention of Samples. Provisions covering Manufacturer’s obligation
to store and retain appropriate samples (identified by Batch number) of Products that it supplies to Merck and access by Merck to the
same are set forth in the Quality Agreement.

 

		5.6	Late Delivery. Without prejudice to the Merck’s rights and
Manufacturer’s obligations under this Agreement, in the event that the Manufacturer is unable to fulfil the Services, regardless
of whether such Services are Development Services or Commercial Manufacturing Services, within the timelines defined under this Agreement,
it shall notify Merck as soon as possible and the Parties will work together to agree a mutually acceptable resolution. If conforming
Product is not received by Merck within [***] from the Delivery Date, except where Manufacturer can reasonably demonstrate that the delay
is not due to its fault (e.g. unavailability of Materials), then Merck shall have the right to claim from Manufacturer payment of a late
performance penalty equal to [***] of the Price of such delayed Manufacturing Run per each calendar day beyond the above [***] grace period,
up to a total amount of [***] of the Price of such delayed Manufacturing Run in total. The foregoing amounts may be deducted by Merck
from any amounts invoiced to Merck. The rights and remedies contained in this Section 5.6 are non-exclusive and without prejudice to Merck’s
right to terminate this Agreement pursuant to Section 19.8 or any other remedy under this Agreement, however, the above late delivery
penalty shall be deducted from any claim of Merck for damages arising from late delivery of a Batch by Manufacturer.

 

		5.7	Manufacturing Problem. In the event that Manufacturer or Merck becomes
aware of any matter, circumstance or event which (i) would reasonably be expected to give rise to a material delay in the shipment of
Product; (ii) reasonably indicate that the quality standards set forth herein and in the Quality Agreement have been materially compromised
or (iii) may reasonably give rise to a material breach hereunder or the right of Merck to terminate this Agreement under ARTICLE 19 (each
a “Manufacturing Problem”), Manufacturer shall promptly give written notice to Merck of such Manufacturing Problem,
the cause thereof, the anticipated length of such Manufacturing Problem, and the action to be taken to reduce, minimize or remove the
adverse effects of any such Manufacturing Problem. Within [***] of receipt of the notice given pursuant to this ARTICLE 5, Merck and Manufacturer
shall meet with a view to agreeing to any actions necessary to ensure that no interruption to supply or shortfall in quantities of any
Product occurs. For purposes of clarity, a Manufacturing Problem which shall give rise to the remedies set forth in this ARTICLE 5 includes,
but is not limited to, (i) receipt by Manufacturer of a warning letter from a Regulatory Authority or a FDA Form 483 affecting a Product,
(ii) continuous errors or inadequacies in batch processing or documentation as determined by Merck in its sole discretion, (iii) circumstances
which could in the reasonable opinion of Merck likely lead to a warning letter from a Regulatory Authority and (iv) delivery of one or
more Batches which do not meet quality standards for the Product as set forth under this Agreement, the Quality Agreement, cGMPs, the
Specifications or Applicable Laws.

 

		5.8	Manufacturing Problem Remediation. In the event that Merck or the
Manufacturer becomes aware of a Manufacturing Problem, the knowledge Party shall give written notice to the other Party of such Manufacturing
Problem (the “Manufacturing Problem Notice”).

 

		(a)	In addition to the actions contemplated in the Quality Agreement, Merck shall have the right to physically
inspect such areas of the Manufacturing Sites that relate to the Manufacturing Problem and Manufacturer shall provide Merck with reasonable
access to all relevant equipment, process, records, appropriate quality system documents and personnel (wherever located) of Manufacturer
associated with the Manufacturing Problem.

 

    15

     

    

 

		(b)	Within [***] of receipt of the Manufacturing Problem Notice, the Steering Committee shall meet with a
view to agreeing on remedial actions in good faith discussions.

 

		(c)	In the event that the Steering Committee cannot agree on remedial actions for the Manufacturing Problem
within [***] of receipt of the Manufacturing Problem Notice, each Party shall have the right to request that an independent expert examines
the root cause for the Manufacturing Problem and renders a respective expert opinion. As soon as possible, the Parties shall agree on
an appropriate independent expert to be engaged by Merck.

 

		(d)	The fees of the independent expert shall be paid by the Party against whom the independent expert’s
decision is made.

 

		(e)	If the Parties or the independent expert (as the case may be) acknowledges that the Manufacturing Problem
cannot be cured within a period of [***] following the Manufacturing Problem Notice and results in a supply shortage in the Territory,
Merck shall have the right to initiate the technology transfer with regard to the Product(s) affected by the Manufacturing Problem and
this Agreement shall terminate upon successful completion of the technology transfer.

 

		(f)	Any and all reasonable costs in fulfilling the technology transfer contemplated by this Section 5.8 shall
be borne by Manufacturer except where Manufacturer can reasonably demonstrate that the Manufacturing Problem is not due to its fault (e.g.
unavailability of Materials or equipment). Nothing contained in this Section 5.8 shall limit any rights or remedies that may be available
to Merck on account of any failure of Manufacturer to supply the Product hereunder.

 

		5.9	Key Performance Indicators. The Parties agree to measure Manufacturer’s
performance of its Development (when applicable) & Commercial Manufacturing Services through the establishment of Key Performance
Indicators (“KPIs”). As long as Manufacturer only delivers up to [***] commercial Batches per year, Manufacturer shall
provide Merck with [***] reports out of its performance based on the KPIs. From [***] Batches per year, the reports should occur [***].
The Parties are currently negotiating these KPIs which will be integrated to this Agreement by way of written amendment signed by both
Parties. If the Parties do not manage to agree on reasonable KPIs within six (6) months from the Effective Date, either Party shall have
the right to terminate this Agreement with immediate effect upon written notice sent in accordance with Section 23.10 to the other Party.
The Parties may agree on additional KPIs by means of further amendments to this Agreement. The Parties shall agree upon the relative importance
of the KPIs by classifying each KPI with a designation of “[***]”, “[***]” or “[***]”. The Parties
shall agree in good faith by [***] of each [***], (beginning with the [***] of the Agreement), the performance level objectives of Manufacturer
for the following [***]. The performance level objectives shall be established for individual KPIs and for overall performance and on
the basis of actual, past performance, and shall be expressed in measurable values. In addition, minimum acceptance levels shall be agreed
upon for all critical KPIs and for overall performance. Manufacturer shall use all Commercially Reasonable Efforts to ensure that its
performance does not fall below these minimum acceptance levels. Notwithstanding Manufacturer’s use of all Commercially Reasonable
Efforts, if at any time Manufacturer’s overall performance or performance for critical KPIs falls below the established minimum
acceptance levels, Manufacturer shall promptly take corrective action to cure such under-performance.

 

    16

     

    

 

		5.10	Process Improvements and Sharing of Costs Efficiencies. Manufacturer
shall monitor potential cost and quality improvements, including by seeking productivity improvements, by minimizing waste and improving
yields, by purchasing quality materials at lower cost, by improving manufacturing processes, by streamlining organizational processes
and by reducing cycle times and lead times. [***] per [***] during the Term, the Parties shall meet to discuss potential improvements
identified by Manufacturer. Merck shall decide whether or not to implement at Merck’s costs necessary changes to achieve the potential
improvements. The Parties shall share [***] of any cost savings so achieved.

 

		5.11	Average Yield. After the Manufacture of the first [***] successful
Manufacturing Runs for validation and commercial purposes, the Parties shall calculate the average yield (“Average Yield”)
of such [***] Manufacturing Runs, disregarding [***]. As from the [***] Manufacturing Run, the price per Manufacturing Run set out in
Section 6.2 below shall be adjusted as follows: if the average yield of all Manufacturing Runs in a campaign is more than [***] higher
or lower than the Average Yield, the price for all Manufacturing Runs of such campaign shall be increased or reduced by applying a surcharge
or discount, as the case may be, of [***] the percentage points beyond such [***] range, e.g. if the average yield of all Manufacturing
Runs of a campaign is [***] below the Average Yield, a discount of [***] shall apply for Manufacturing Runs of such campaign. For the
avoidance of doubt, in case the investigation of the low yield shows a technical failure due to Manufacturer’s fault, then the price
for all Manufacturing Runs of such campaign will be reduced by the difference below the [***], i.e, if the average yield of all Manufacturing
Runs of such campaign is [***] below the Average Yield, a discount of [***] shall apply for all Manufacturing Runs of such campaign. Price
[***] will be discussed and implemented once sufficient data are available.

 

Article
6

PRICE

 

		6.1	Development Services. In consideration of the performance by Manufacturer
of the Development Services, Merck shall pay Manufacturer the amounts specified in Schedule 1.

 

		6.2	Manufacturing Runs for commercial purposes. In consideration of each
Manufacturing Run, Merck agrees to pay to Manufacturer, in addition to the further costs and charges as set out in this Agreement, an
amount of

 

	 	[***]	for each of the first [***] Manufacturing Runs in a [***] (based on the agreed Delivery Date),
	 	 	 
	 	[***]	for each of the [***] to [***] Manufacturing Runs in a [***] (based on the agreed Delivery Date),
	 	 	 
	 	[***]	for each of the following [***] to [***] Manufacturing Runs in a [***] (based on the agreed Delivery Date), and
	 	 	 
	 	[***]	for each further Manufacturing Run in a [***] (based on the agreed Delivery Date),

 

All the above mentioned prices include
production costs, Batch Documentation and IPC testings.

 

		6.3	Raw Materials and Consumables. Costs of Materials and consumables
to be used by the Manufacturer in the performance of the Services are not included in the fees under Sections 6.1 and 6.2 and shall be
passed on to Merck at cost plus [***] handling fee. Costs of [***] shall be passed on to Merck at a cost plus [***]. Merck is aware that
the consumption and prices of Materials and consumables vary from Manufacturing Run to Manufacturing Run. If an increase of total costs
of Materials or consumables by more than [***] occurs, Manufacturer will give Merck sufficient and detailed information about the increase
in costs for such Materials or consumables to reasonably demonstrate that the increase of the costs is justified. Upon request of Merck,
Manufacturer will share the specific supplier invoices of such Materials or consumables.

 

    17

     

    

 

		6.4	Packing and Qualification of Columns. Manufacturer shall be entitled
to charge for the packing and qualification of each column a lump-sum amount of [***]. Costs for spare parts for the columns are not included
and shall be passed on to Merck at cost plus a [***] handling fee.

 

		6.5	Filling of Stability Samples. Manufacturer shall be entitled to invoice
for the filling of stability samples required for the performance and testing of stability studies performed at Merck an amount [***]
for up to [***] bags. The costs for external testing ([***]) and transport of analytical samples and stability samples are not included
and shall be passed on to Merck at cost plus [***] handling fee.

 

		6.6	Annual Product Review. Manufacturer shall be entitled to charge for
the annual product review an amount [***] per review.

 

		6.7	Project Management. Manufacturer shall be entitled to charge for
overall project management services [***] per [***].

 

		6.8	Regulatory Support. Manufacturer shall be entitled to charge for
regulatory support as set out in Section 13.9.

 

		6.9	External Analytical Testing. Costs of external analytical testing
for [***], [***] and [***] are not included and shall be passed on to Merck at cost plus a [***] handling fee.

 

		6.10	Transport of the Samples. In the event Manufacturer organizes the
transport of the samples to Merck or any third party including Manufacturer’s subcontractors, transport costs shall be passed on
to Merck at cost. Manufacturer shall bear the risk of loss during the transport of samples to/from its subcontractors. Merck shall bear
the risk of loss during any other transport of samples starting from the moment Manufacturer hands over a sample to the courier service,
including but not limited to the transport from Manufacturer to Merck.

 

		6.11	Storage of Columns. Manufacturer shall be entitled to charge Merck
for storage for columns that are not used during [***] consecutive [***] [***] per [***] per column for each [***] following the [***]
period.

 

		6.12	Potential Extra Costs. In addition to the above, Manufacturer shall
be entitled to charge Merck costs and expenses of (i) changes to documentation, e.g. due to a request of a Regulatory Authority, (ii)
the potential requirement of an [***] before production of the Drug Substance, (iii) reporting in the context of the continuous process
verification (iv) concurrent lifetime and hold time studies (reports) for [***], and (v) any stability study.

 

		6.13	Costs of Process-Dedicated Equipment. Where the performance of the
Services requires Manufacturer to purchase any process-dedicated equipment (such as [***]) and when Merck consents in writing to it in
advance, such consent not to unreasonably withheld, delayed or conditioned, Manufacturer shall be responsible for purchasing such process-dedicated
equipment, for the implementation of such process-dedicated equipment at its facilities as required for the purposes of the Services,
and for qualifying and maintaining such process-dedicated equipment. Manufacturer shall only purchase such process-dedicated equipment
upon prior approval by Merck, for which Manufacturer shall provide Merck with a quotation from its supplier. Merck shall be responsible
for any delay in the performance of the Services caused by a failure on the part of Merck to approve the purchase of such process-dedicated
equipment within a reasonable time from being requested to do so by Manufacturer. Manufacturer shall also include the costs of such process-dedicated
equipment as a separate item plus a [***] handling fee in its invoices for the Services. It is understood and agreed that, upon Merck
paying the invoice that itemizes such process-dedicated equipment, Merck shall become the owner of such process-dedicated equipment, but
shall allow Manufacturer to use such process-dedicated equipment for the purposes of the Services. Any process-dedicated equipment shall
be used only for the purposes of the Services, and shall promptly be returned to Merck upon termination of this Agreement for any reason.
Notwithstanding the above, Manufacturer shall purchase the first set of [***] at its own expense. In the event Merck does not order any
commercial Batches under this Agreement, Manufacturer shall be entitled to invoice to Merck such first set of [***] at [***].

 

    18

     

    

 

		6.14	Storage. Manufacturer shall be entitled to charge Merck for the storage
of Products in accordance with the Storage Agreement, however, only alter the first [***] of storage of Products.

 

		6.15	Travelling Costs. Merck shall reimburse travelling expenses as may
be reasonably incurred by Manufacturer in the course of the direct performance of the Services provided that (i) such expenses have been
previously agreed upon in writing by Merck; (ii) such expenses will be based on 2nd class/economy class travel for all travels within
Europe, unless agreed to otherwise in advance and in writing by Merck (with expenses for travel outside Europe to be agreed in advance
and in writing); and (iii) that the reimbursement requests are accompanied with appropriate supporting evidence of such expenses.

 

		6.16	Agreed Hourly Rate. The initial Agreed Hourly Rate shall be [***].
The hourly rate for formal validation support shall be [***].

 

		6.17	Indexation. Except for pass-through costs, all amounts payable to
Manufacturer under this Agreement as well as the Agreed Hourly Rate shall be revised upwards or downwards each year in accordance with
the increase or decrease, as the case may be, of the harmonized German consumer price index published by the German Federal Statistical
Office (Statistisches Bundesamt) on their official website (https://www.destatis.de) from January of the previous year to January
of the then current year and invoices from Manufacturer to Merck from April onwards shall take such increase or decrease into account,
e.g., if such index increases by zero point nine percent (0.9%) between January 2018 and January 2019, all amounts payable to Manufacturer
which are invoiced on or after 1 April 2019 shall also increase by zero point nine percent (0.9%). However, just yearly increase or decrease
cannot exceed [***] For the avoidance of doubt, the value of such index in December 2017 was 110.6 (on basis 2010 = 100). Manufacturer
shall not be entitled to delay an invoice in order to charge the new increased amount instead of the applicable old amount. This clause
shall apply for the first time as per [***], taking into account change of the German consumer price index from [***] to [***] and thereafter
on a yearly basis.

 

		6.18	Taxes. All payments under the Agreement are deemed exclusive of VAT
or any other indirect taxes; The invoicing Party shall, if required under applicable laws & regulations, add VAT or any other indirect
taxes to the Price at the prevailing rate under applicable laws & regulations; the invoicing Party shall also fulfill all material
and formal conditions required from the invoicing Party under applicable laws & regulations to ensure a refund of the VAT or any other
indirect taxes charged to the invoiced Party provided a refund is available to the invoiced Party under applicable laws & regulations.

 

    19

     

    

 

		6.19	Tax Withholding. The amounts payable by one Party (the “Payer”)
to another Party (the “Payee”) pursuant to this Agreement (“Payments”) shall not be reduced on account
of any Taxes unless required by law. The Payee alone shall be responsible for paying any and all Taxes (other than withholding Taxes required
to be paid by the Payer) levied on account of, or measured in whole or in part by reference to, any Payments it receives. The Payer shall
deduct or withhold from the Payments any Taxes that it is required by law to deduct or withhold. Notwithstanding the foregoing, if the
Payee is entitled under any applicable Tax treaty to a reduction of rate of, or the elimination of, or recovery of, applicable withholding
Tax, it shall promptly deliver to the Payer or the appropriate Governmental Authority (with the assistance of the Payer to the extent
that this is reasonably required and is expressly requested in writing) the prescribed forms necessary to reduce the applicable rate of
withholding or to relieve the Payer of its obligation to withhold Tax, and the Payer shall apply the reduced rate of withholding, or dispense
with the withholding, as the case may be. If, in accordance with the foregoing, the Payer withholds any amount, it shall make timely payment
to the proper Governmental Authority of the withheld amount, and send to the Payee reasonable proof of such payment within sixty (60)
days following that payment. If Taxes are paid to a tax authority, each Party will provide the other such assistance as is reasonably
required to obtain a refund of Taxes withheld, or obtain a credit with respect to Taxes paid.

 

Article
7

INVOICES AND PAYMENT

 

		7.1	Invoices. Manufacturer shall invoice Merck in accordance with ARTICLE
6. Each invoice shall specify the Price in respect of the Products delivered, the quantity of Batches of the Products delivered and the
amount of sales, use, value added, excise or equivalent indirect tax due in respect of the Products delivered and the Purchase Order reference
number. Manufacturer’s invoices shall comply with all Applicable Laws.

 

		7.2	Payment of Invoices. Merck shall pay the invoices issued by Manufacturer
in Euro within [***] from the date of receipt of the invoice by electronic transfer to the account nominated in writing by Manufacturer,
except in case of any Product rejected in accordance with ARTICLE 9. In case of rejection, the term of payment will start once the delivery
is accepted by Merck. In case Manufacturer will store Product free of charge at Merck’s demand at Manufacturer’s premises,
payment process will be triggered at reception of the Batch Documentation.

 

Article
8

QUALITY ASSURANCE

 

		8.1	Validation Studies. Manufacturer shall perform validation studies
as agreed between the Parties in writing, or to the extent required by the Specifications, cGMP or Applicable Laws to manufacture the
Products at the Manufacturing Site.

 

		8.2	Analytical Reference Standards. Merck shall provide, without charge
to Manufacturer, analytical reference standards for the Products. The reference standards shall be provided in quantities reasonably required
for Manufacturer to perform its obligations relating to the manufacture, stability testing or any other testing of the Products under
this Agreement.

 

    20

     

    

 

		8.3	Technical and Quality Matters. The respective responsibilities of
each Party in relation to technical and quality matters connected to the performance of the Services are further set out in the Quality
Agreement.

 

		8.4	Release Testing. Prior to release of the Products to finished goods
inventory, Manufacturer shall test the Products in accordance with the testing procedures for bioburden (external lab), content by[***]
described in the Specifications. All other release testing procedures will be performed by Merck.

 

		8.5	Man-in-Plant. Manufacturer agrees that, at Merck’s option,
Merck representatives may be present at the Manufacturing Site (including adequate temporary desk space and other reasonable resources
available to these representatives during the periods they are at the Manufacturing Site) during the performance of certain Services and
manufacturing of Product(s) for the purposes of inspecting, sampling, check weighing, and documenting the manufacturing of the Product(s)
and all associated records in connection therewith. Any Merck employees who are present at the Manufacturing Site shall comply with Manufacturer’s
site regulations and rules. The Merck representative, if present, does not have responsibility for the supervision of Manufacturer’s
personnel or the manufacturing of the Product(s). However, if at any time the Merck representative thinks that Manufacturer is operating
in a manner not compliant with the know-how or which could adversely affect the manufacturing of Product(s), he/she may recommend that
Manufacturer cease operations until such condition is remedied.

 

Article
9

DEFECTIVE PRODUCTS AND DEFECTIVE SERVICES

 

		9.1	Warranty. Subject to Section 18.3, Manufacturer warrants to Merck
that at the time of delivery of any Batch of the Product: (i) as far as Services performed by Manufacturer, its Affiliates and/or subcontractors
are concerned, the Batch will have been manufactured in accordance with the relevant conditions applicable hereunder as specified in the
relevant Work Order or Purchase Order; (ii) each Batch will only be released by Manufacturer if it has passed the Quality Control Procedure
conducted by Manufacturer and Merck whereby Manufacturer may, in the process of its Quality Control Procedure, unconditionally rely on
all data provided by Merck; (iii) as far as Services performed by Manufacturer, its Affiliates and/or subcontractors are concerned the
Batch will be manufactured using and in accordance with the Manufacturing Process and in accordance with cGMP, the Services Related Requirements
of the Specifications, the provisions of the Quality Agreement and Applicable Laws. Further, Manufacturer warrants and represents to Merck
(i) that, during the Term of this Agreement, Manufacturer will have obtained and maintained such approvals and licenses as may be required
under applicable laws, rules, regulations and requirements to operate its manufacturing facilities for the purposes contemplated by this
Agreement, and (ii) as far as Services performed by Manufacturer, its Affiliates and/or subcontractors are concerned that Batch Documentation
shall be generated and stored in accordance with cGMP, the Services Related Requirements of the Specifications, the provisions of the
Quality Agreement and Applicable Laws.

 

		9.2	Non-conforming Batch. Where Manufacturer or Merck, through own sample
analysis before delivery of a Batch, finds that any Batch fails or will fall to comply with any Product Related Requirements of the Specifications,
including but not limited to the release specifications (i) Manufacturer or Merck, as the case may be, shall notify the other Party thereof
within [***], (ii) Manufacturer shall not deliver the Batch, (iii) Manufacturer shall, upon request by Merck in case Manufacturer
had not already provided samples, promptly provide Merck with samples of the Batch in order to allow Merck to perform its own analysis
of the failed Batch; (iv) at the latest within [***] of the first notification, Manufacturer shall provide Merck with a written report
summarizing results of Manufacturer’s investigation of the cause of such failure, and (v) the Parties shall thereafter discuss in
good faith said failure and consider which optimization or correction shall be implemented by Manufacturer in order to perform another
Batch, which additional Manufacturing Run, if mutually decided, shall be subject to the execution of a written amendment to the respective
Work Order or Purchase Order which shall set forth the new terms and conditions or such additional Manufacturing Run. In case the non-compliance
of said Product is determined to have arisen from Manufacturer’s breach of the warranties set out in Section 9.1, Sections from
9.6 to 9.9 shall apply. In case the non-compliance of said Product is determined not to have arisen from Manufacturer’s breach of
the warranties set out in Section 9.1, Merck may request Manufacturer to perform, at Merck’s sole cost, an additional Manufacturing
Run and produce a new cGMP Batch replacing the rejected cGMP Batch as soon as reasonably possible. Notwithstanding the foregoing, Merck
shall have the unfettered right to discretionary decide not to perform an additional production Service. For clarity: Merck shall pay
Manufacturer the applicable Price for a Manufacturing Run despite the fact that a non-conforming Product was generated unless such non-compliance
was caused by Manufacturer’s breach of the warranties set out in Section 9.1 and rejected by Merck in accordance with Section 9.6.
In case the non-compliance of said Product is determined to have arisen from Manufacturer’s failure to perform the Services in accordance
with the warranties set out in Section 9.1, Section 9.6 shall apply. In case the reason for the non-compliance cannot be determined, Merck
shall pay Manufacturer [***] of the applicable Price for the respective Manufacturing Run.

 

    21

     

    

 

		9.3	Acceptance, Rejection of Product. Merck will notify Manufacturer
in writing of its acceptance or rejection of any shipment of Product hereunder within [***] of the [***] receipt of any [***], including
but not limited to the [***], and within [***] of the [***] receipt of [***] to Merck or to the third party designated by Merck or, in
the case of any defects not reasonably susceptible to discovery upon receipt, within [***] after discovery by Merck or third party designated
by Merck. For clarity: the aforementioned notice periods shall in any case not start during storage of the containers containing the Product
at Manufacturer as the containers containing the Product need to be physically received by Merck or a third party designated by Merck.
Merck has no obligation to accept such Products if they do not comply with any warranty set out in Section 9.1. In the absence of any
such written notification of Merck to Manufacturer within the applicable time period set out above, containing in reasonable detail the
reasons of the non-conformance, the applicable Product shall be deemed to comply with and accepted by Merck (“Acceptance”).
Upon receipt of a Product, Merck shall retain full control and title to the relevant Product and shall transport and store (or shall ensure
that the third party designated by Merck shall transport and store) such Product under appropriate and controlled conditions compliant
with cGMP requirements. Any other use or processing of such Product by or on behalf of Merck [***] shall be at the sole risk, responsibility
and expense of Merck and shall constitute an unconditional Acceptance of such Product. This Section 9.3 shall apply to both (i) the shipment
of the Batch Documentation to Merck as well as (ii) the shipment of the Product itself. In the former event, the Acceptance relates to
the Batch Documentation, i.e. the compliance of the Product with any warranty as set out in Section 9.1, while in the latter event the
Acceptance relates to the primary packaging of the Product.

 

		9.4	Resolution of Dispute as to Whether a Product is Non-Conforming.
The Parties shall cooperate in good faith to determine whether a rejection of Product is appropriate. If the Parties disagree, a sample
of the rejected Product and a sample retained by Manufacturer shall be exchanged between Merck (or a third party designated by Merck reasonably
acceptable to Manufacturer) and Manufacturer for a counter-check. If such counter-check does not resolve the dispute, a sample of the
rejected Product and a sample retained by Manufacturer shall be submitted to an independent, qualified Independent Expert that is mutually
acceptable and selected by Manufacturer and Merck promptly in good faith. Such Independent Expert shall determine whether the rejected
deliverable met the warranties set out in Section 9.1 at the time of delivery by Manufacturer to Merck or to the third party designated
by Merck, as applicable and such Independent Expert’s determinations shall be final, binding upon the Parties and determinative
for purposes of this Agreement. The Party against whom the Independent Expert rules, shall bear all costs of the Independent Expert.

 

    22

     

    

 

		9.5	Conforming Product. If the Parties have agreed, or if the Independent
Expert determines that the Product was conforming in all respect with the warranties set out in Section 9.1 at the time of delivery by
Manufacturer then such Product shall be deemed to have been accepted by Merck, and Merck shall make the final payment therefor in accordance
with ARTICLE 6.

 

		9.6	Non-Conforming Product. If the Parties have agreed or if the Independent
Expert determines that the Product was not conforming to the warranties set out in Section 9.1 at the time of delivery by Manufacturer
then such Product shall be deemed to have been rejected by Merck, and Manufacturer shall refund to Merck all payments made by Merck therefore
in accordance with ARTICLE 6.

 

		9.7	Responsibility of Manufacturer. For the avoidance of doubt, Manufacturer
shall not be responsible for (and Merck shall pay the Price for such Manufacturing Run in full) if the reason for the non-compliance of
the Product is for any other reason but for a breach of the warranties set out in Section 9.1, such other reason being for example [***].
Accordingly, Manufacturer shall also not be responsible for any delay or non-performance of Services of Manufacturer caused by reasons
outside of Manufacturer’s responsibility (e.g. [***]), if Manufacturer took all reasonable actions to prevent such delay or non-performance
of the Services.

 

		9.8	Sole Remedy. It is specifically agreed that, in addition and without
prejudice to what is set out in Sections 5.6, 18.1 and ARTICLE 19, the actions described in this ARTICLE 9 shall be the sole remedy of
Merck in the event any Product supplied by Manufacturer in the context of Commercial Manufacturing Services fails to conform to the warranties
set out in Section 9.1. The limitation of remedies set out herein shall not apply in case of failure by the Manufacturer to perform its
obligations hereunder due to the Manufacturer’s wilfull misconduct or gross negligence unless Manufacturer’s gross negligence
in the performance of its obligations hereunder has resulted into a Defect in a Batch ordered by Merck and Manufacturer, at Merck’s
request, offers and successfully performs at its own costs a new Manufacturing Run under the terms and conditions of Section 9.9.

 

		9.9	Defective Services. In the event that Manufacturer is not properly
performing Development Services pursuant to this Agreement, except where Manufacturer can reasonably demonstrate that such malperformance
is not due to its fault (e.g. [***]), Manufacturer shall, at Merck’s option, either re-perform as set out below at its own costs
the defective Development Services in accordance with the Specifications and this Agreement or refund to Merck the price and/or any advance
payments paid for such defective Development Services. For the avoidance of doubt, in the event that Merck opts for the re-performance
of defective Development Services consisting in the re-performance of Manufacturing Runs, Manufacturer shall use its best efforts to schedule
the start of such new Manufacturing Runs as early as possible and anyway not later than a maximum of [***] from Merck’s request
for the reperformance of the defective Development Service or, as the case may be, not later than a maximum of [***] after the root cause
identification of the Defect affecting the Batch to be replaced. In order to secure a quicker slot, Merck shall also have the option to
reserve one or several back-up Manufacturing Runs by issuing one or more Work Orders at least [***] prior the Delivery Date. In case such
back-up Manufacturing Run(s) is/are needed due to a failure by the Manufacturer to perform its obligations hereunder, no cost will be
charged by the Manufacturer to Merck for such back-up Manufacturing Run(s). If the ordered back-up Manufacturing Run(s) is/are not needed
and the relevant Work Order is cancelled by Merck, Merck shall pay in derogation of Section 4.8 a lump-sum of [***] as cancellation fee
independently of the time when the cancellation of the Work Order occurred unless the reallocation of such back-up Manufacturing Run(s)
is possible under Section 4.9 excluding Merck’s obligation to pay a cancellation fee. In addition and without prejudice to what
is set out in Sections 5.6, 18.1 (for the case of death and bodily injuries) and ARTICLE 19, the remedies set out in this Section 9.9
shall be Merck’s sole and exclusive remedies under this Agreement with respect to any defective Development Services and any delay
caused by defective Development Services. The limitation of remedies set out herein shall not apply in case of failure by the Manufacturer
to perform a Development Service due to the Manufacturer’s wilfull misconduct or gross negligence unless Manufacturer’s gross
negligence in the performance of its obligations hereunder has resulted into a Defect in a Batch ordered by Merck and Manufacturer, at
Merck’s request, offers and successfully performs at its own costs a new Manufacturing Run under the terms and conditions of this
Section 9.9.

 

    23

     

    

 

Article
10

PRODUCT LICENSES

 

Merck shall, at its expense, obtain and maintain
all necessary Product Licenses. Merck shall be responsible for responding to all requests for information related to such Product Licenses
made by, and for making all legally required filings relating to such Product Licenses with, any Regulatory Authority having jurisdiction
to make such requests or require such filings. If any Product License held by Merck relating directly to the Products is hereafter suspended
or revoked, Merck shall promptly notify Manufacturer of the event and shall promptly inform Manufacturer of the Impact an Merck’s
purchases of the affected Products and Merck’s general intentions with respect to the affected Product.

 

Article
11

TRIAL AUTHORIZATION

 

Merck or a Merck’s designated third party
shall, at its expense, obtain and maintain all necessary Trial Authorizations. Merck or a Merck’s designated third party shall be
responsible for responding to all requests for information related to such Trial Authorizations made by, and for making all legally required
filings relating to such Trial Authorizations with, any Regulatory Authority having jurisdiction to make such requests or require such
filings. If any Trial Authorization held by Merck or a Merck’s designated third party relating directly to the Products is hereafter
suspended or revoked, Merck shall promptly notify Manufacturer of the event and shall promptly inform Manufacturer of the impact on Merck’s
purchases of the Product and Merck’s general intentions with respect to the Trial.

 

Article
12

CHANGES TO PRODUCT SPECIFICATIONS

 

		12.1	Changes Requested by Manufacturer. Notwithstanding anything herein
to the contrary, Manufacturer shall not amend, change or supplement any of the following except in accordance with the change control
provisions set forth in the Quality Agreement: (a) the Specifications, (b) the Materials, (c) the source of Materials, (d) the specifications
for Materials, (e) the Manufacturing Site or the equipment used in manufacturing the Product, (f) the test methods used to test the Products
or Materials, or (g) the process for manufacturing the Products (each of the foregoing a “Technical Change”).

 

		12.2	Changes Requested by Merck. Merck may request a Technical Change
by written notice to Manufacturer, and except as prohibited by Applicable Law, Manufacturer shall use Commercially Reasonable Efforts
to implement such change within a reasonable period of time.

 

    24

     

    

 

		12.3	Required Manufacturing Changes. Each Party shall notify the other
Party of any Technical Change which is required by cGMPs or Applicable Laws (a “Required Manufacturing Change”). Manufacturer
shall use Commercially Reasonable Efforts to implement Required Manufacturing Changes within a reasonable period of time.

 

		12.4	Cost of Technical Changes All reasonable out-of-pocket costs associated
with Required Manufacturing Changes that relate to the Product or to the performance of any Services (including the cost of any Regulatory
Authority filings and any write offs and other similar costs due to such changes associated with obsolete Materials, work-in-process and
finished Product inventories, and printed materials, including packaging and labelling materials) shall be borne by Merck, except with
respect to Materials purchased by Manufacturer in excess of the amounts needed to fulfil Manufacturing Runs set out in the Firm Zone,
unless otherwise procured by Manufacturer in advance with Merck’s consent (provided that Manufacturer will use Commercially Reasonable
Efforts to minimize the costs associated therewith).

 

		12.5	Technical Change Implementation. All Technical Changes (including
Required Manufacturing Changes) shall be implemented in accordance with Applicable Laws, cGMP and the Quality Agreement. Prior to implementation
of any Technical Change, the Parties shall ensure that any implications on the quality of the Products have been considered and recorded,
and the change is approved by the relevant Regulatory Authorities. Manufacturer shall provide Merck with technical assistance at the Agreed
Hourly Rate, including through the provision of supporting documentation in order to permit Merck to amend and file any relevant document
required to be filed with a Regulatory Authority.

 

Article
13

QUALITY & REGULATORY COMPLIANCE

 

		13.1	Maintenance of Permits. Manufacturer shall maintain all Manufacturing
Licenses and other regulatory and governmental permits, licenses and approvals that may be necessary to Manufacture Product.

 

		13.2	Notification of Adverse Manufacturing Activities. Manufacturer shall
advise Merck of any information arising out of its Services that has adverse regulatory compliance and/or reporting consequences concerning
the Product.

 

		13.3	Activities at the Manufacturing Site and Machinery Used to Manufacture
Products. Manufacturer shall not carry out any other activities at the Manufacturing Site that may prejudice the quality, safety or
efficacy of the Products.

 

		13.4	Storage. Manufacturer shall at all times store and warehouse all
Materials and Products in premises that are secure, clean, compliant with the Specifications, Manufacturing Licenses and the Quality Agreement
and otherwise reasonably acceptable to Merck and shall be physically separated from all other materials and products in Manufacturer’s
possession. Manufacturer shall be responsible for the safe storage and handling of the Products until delivery to Merck in accordance
with the Delivery Terms. The Manufacturer shall keep records of the storage conditions in relation to each Batch of Products in accordance
with the requirements set forth in the Quality Agreement. Manufacturer agrees to disclose to Merck from time to time or upon Merck’s
request, subject to Manufacturer’s confidentiality obligations to its other customers, the nature of any relevant products manufactured
or packaged by Manufacturer for itself or third parties which use the same machinery as that used by Manufacturer for the Manufacture
of Products under this Agreement or that are stored in the same location where the Products or Materials are stored in order that Manufacturer
and Merck may identify any potential effects on quality, safety or efficacy of the Products which may result.

 

    25

     

    

 

		13.5	Requests from and Inspections by Regulatory Authorities. Provisions
covering correspondence, interaction with and provision of information to Regulatory Authorities, including inspections, are set forth
in the Quality Agreement.

 

		13.6	Audits by Merck. Representatives of Merck may, upon reasonable notice,
at times reasonably acceptable to Manufacturer and in accordance with the further terms and conditions agreed in the Quality Agreement,
(i) visit, inspect and audit the Manufacturer’s facilities where the Services are being performed, and (ii) consult informally,
during such visits and by telephone, with personnel of Manufacturer performing work on the Services; provided, however, that Manufacturer
shall accompany each on Merck’s initial visit to Manufacturer’s facilities. Any such visits will be coordinated with a representative
of Manufacturer to be designated in writing following execution of this Agreement.

 

In addition, Merck shall also be entitled,
upon prior written notice to Manufacturer, to conduct audits “for cause” which shall include, without limitation, manufacturing
or facility issues affecting the Manufacture of the Product or quality of the Product (including cGMP), at times reasonable acceptable
to Manufacturer, but in any case no later than [***] from receipt by Manufacturer of said prior written notice. Merck shall not be charged
by Manufacturer for any audit made “for cause”.

 

Any information and data disclosed to
Merck pursuant to this Section 13.6 shall be deemed Confidential Information subject to the obligations of confidentiality and non-use
as provided in ARTICLE 16.

 

		13.7	Audit and Inspection Fees. Manufacturer shall be entitled to charge
for the costs of audit and inspections at the agreed hourly rate except for [***] audit every [***] which shall be [***]. In addition,
Manufacturer shall not be entitled to charge any amounts to Merck where an audit or inspection is “for cause”.

 

		13.8	Handling of Materials; Wastes. Manufacturer shall inform its employees,
contractors and other personnel of any known or reasonably ascertainable chemical hazards associated with the Products or any wastes (including,
Hazardous Materials) generated through performance of the Services, and to provide such persons with reasonable training in the proper
methods of handling and disposing of such items. In addition, Manufacturer shall handle, accumulate, label, package, ship and dispose
of all wastes (including, Hazardous Materials) generated through performance of the Services in accordance with all Applicable Laws.

 

		13.9	Documentation for Regulatory Authority Requirements. Manufacturer
shall maintain in accordance with and for the period specified in the Quality Agreement (unless cGMP or Applicable Laws require a longer
period), complete and accurate records relating to the manufacture of Products and to the performance of Services as it may be required
to hold under such Applicable Law. Manufacturer shall provide Merck with such documentation promptly upon Merck’s request.

 

		13.10	Assistance with Regulatory Filing. Manufacturer shall prepare and
provide to Merck, at no additional cost (unless otherwise agreed to in writing by the Parties), the reports agreed and described in Schedule
5 supporting manufacturing operations for the Products (including, without limitation, [***]) for Merck’s use in updating the
[***] of the applicable IND/CTA and/or NDA/BLA. The above-mentioned reports might be used as is in regulatory submission or in the framework
of response to questions. Assistance to provide response to questions received from authorities should be provided within the due evaluation
timelines as appropriate and at Merck’s expense as described in Schedule 5, except in case of deficiency of Manufacturer’s
Services in which case Merck shall not pay for such Services. Manufacturer shall provide at the Agreed Hourly Rate mentioned in Section
6.16 further regulatory assistance as may reasonably be required by Merck.

 

    26

     

    

 

		13.11	Debarment and Exclusion. Manufacturer represents and warrants that
neither it, its subcontractors, nor any individual, corporation, partnership or association engaged in connection with the performance
of services under this Agreement, has ever been, are currently, nor during the performance of any services hereunder, shall become:

 

		(i)	disqualified or debarred by the FDA or other competent Regulatory Authorities for any purpose pursuant
to Applicable Laws (including but not limited to United States law, including but not limited to the statutory debarment provisions at
21 U.S.C. § 335a(a) or (b));

 

		(ii)	charged or convicted for conduct relating to the development or approval of, or otherwise relating to
the regulation of, any drug product under any Applicable Laws; or

 

		(iii)	excluded or threatened with exclusion under state or federal laws, including under 42 U.S.C. § 1320a-7
or relevant regulations in 42 C.F.R. Part 1001, or assessed or threatened with assessment of civil money penalties pursuant to 42 U.S.C.
Part 1003.

 

Manufacturer agrees to notify Merck immediately,
in the event that Manufacturer or any of its officers, directors, employees, agents, or parties under contract to perform and work under
this Agreement (i) becomes debarred, excluded or convicted, or (ii) receives notice of action with respect to its debarment, exclusion
or conviction during the Term. Manufacturer hereby certifies that it has not utilized, and shall not utilize, in any capacity the services
of any individual, corporation, partnership or association in the performance of work for Merck under this Agreement that has been (X)
debarred, or to its knowledge has received notice of action with respect to debarment, under the Generic Drug Enforcement Act of 1992,
21 United States Code §335a(a) and (b), as amended or any foreign equivalent thereof, (Y) excluded pursuant to 42 U.S.C. § 1320a-7
or relevant regulations in 42 C.F.R. Part 1001 or to its knowledge has received notice of exclusion or any foreign equivalent thereof
or (Z) otherwise convicted pursuant to (ii) above, or to its knowledge has received notice of conviction or any foreign equivalent thereof.
In the event that Manufacturer receives any notice of actions set forth in this Section 13.110 (with regard to Manufacturer only but not
including an individual employee, officer, director, agent or subcontractor), without limiting any other rights or remedies of Merck,
Merck shall have the right to terminate this Agreement immediately pursuant to the provisions of this Agreement. Any termination by Merck
pursuant to this Section 13.11 shall be deemed to be a termination by Merck for material breach of this Agreement by Manufacturer pursuant
to Section 19.7.

 

		13.12	Compliance with REACH. Merck Manufacturer shall ensure compliance
with the Registration requirements stipulated in Regulation (EC) No. 1907/2006 (“REACH”) with respect to Products manufactured
and Raw Materials required by Manufacturer. Merck shall, at its expense, be responsible for responding to regulatory developments with
impact on the manufacturing process, such as the inclusion of Raw Materials in Annex XIV to the Reach regulation (“Authorization”),
and to decide on the approach chosen, such as technical changes to substitute substances of concern, or regulatory action to satisfy the
requirements.

 

    27

     

    

 

Article
14

OPERATIONAL MANAGEMENT; STEERING COMMITTEE

 

		14.1	During the Term, the operational management of the relationship between
the Parties shall lie with the Steering Committee established by the Parties in accordance with this ARTICLE 14.

 

		14.2	The Steering Committee shall be composed of [***] representatives of each
Party but of at least one member of the management of each Party and one additional representative of each Party. It shall have the general
responsibility for the implementation of the Clinical and Commercial Supply Agreement. The Steering Committee’s resolutions shall
be adopted unanimously, with an escalation to the Parties’ senior management in the event of a blockage or tie.

 

		14.3	The tasks of the Steering Committee shall include, without limitation:

 

		(a)	periodically review the KPIs outlined in Schedule 2, and update such KPIs as may be required;

 

		(b)	consider and, when appropriate, approve amendments to the Material Specifications;

 

		(c)	periodically review the level of the Manufacturer’s Safety Stocks and adjust their level as deemed
necessary, as contemplated in Section 2.13;

 

		(d)	work on a mutually acceptable resolution to minimize the consequences of a late delivery, as contemplated
in Section 5.6; and

 

		(e)	agree on remedial actions to address Manufacturing Problems, as contemplated in Section 5.8.

 

		14.4	The Steering Committee shall pass its resolutions:

 

		(a)	in meetings on the occasion of which all members are present (either in person or through voice or video
conferencing systems); or

 

		(b)	by written consent to a proposal submitted by one of their members.

 

Article
15

PRODUCT COMPLAINTS AND ADVERSE EVENTS

 

		15.1	Product Complaints, Adverse Events and Product Events. Provisions
covering complaints or Adverse Events are set forth in the Quality Agreement. Provisions covering voluntary and involuntary recalls, product
withdrawals, field corrections, field alerts, or other related actions (“Product Event”) of Finished Medicinal Products
are set forth in the Quality Agreement.

 

		15.2	Expenses Resulting from a Product Event. In the event that a Regulatory
Authority requires, or Merck decides to, initiate a Product Event with respect to a Finished Medicinal Product using Product manufactured
by Manufacturer under this Agreement, Merck shall promptly notify Manufacturer. Manufacturer shall fully cooperate with Merck in implementing
the foregoing as Merck or the Regulatory Authority may require. If the Product Event is due to a breach of this Agreement by Manufacturer
or Manufacturer’s negligence or wilful misconduct, Manufacturer shall replace all Products used for manufacturing recalled Finished
Medicinal Products, at Manufacturer’s cost.

 

    28

     

    

 

Article
16

CONFIDENTIALITY AND DATA PROTECTION

 

		16.1	Non-Use, Non-Disclosure. Manufacturer shall use the Confidential
Information only for the purpose of providing Development and Commercial Manufacturing Services hereunder. Except as otherwise provided
for herein, Manufacturer shall not, at any time (whether during this Agreement or alter its termination) use, for Manufacturer’s
own or any Third Party’s benefit or purposes or disclose, publish or make available all or any portion of the Confidential Information
to any other Third Party, without the Prior written consent of Merck. Merck Background IP and Merck Arising IP shall be considered the
Confidential Information of Merck.

 

		16.2	Standard of Care. Manufacturer shall maintain and protect the confidentiality
of Confidential Information and shall use at least the same degree of care to safeguard and to prevent disclosing of Confidential Information
as it employs to avoid unauthorized disclosure, publication, dissemination, destruction, lass, or alteration of its own confidential information
(or information of its customers of a similar nature), but at all times shall use at least reasonable care. Manufacturer shall implement
and maintain appropriate security measures to prevent unauthorized access to, or disclosure of Confidential Information. Manufacturer
personnel and approved subcontractors shall have access to Confidential Information Only to the extent necessary for such person to perform
his or her obligations under or with respect to this Agreement or as otherwise naturally occurs in such person’s scope of responsibility,
provided that such access is not in violation of Applicable Law.

 

		16.3	Required Disclosures. The obligations of confidentiality, non-disclosure
and non-use hereunder shall continue until the relevant Confidential Information falls within the exceptions provided for in Section 16.4
hereof. Notwithstanding the foregoing, Manufacturer shall be entitled to disclose the Confidential Information to the extent required
by Applicable Law or court order on the condition that Manufacturer provides Merck with written notice that the Confidential Information
is required to be disclosed sufficiently in advance of the disclosure so as to provide Merck with reasonable opportunity to seek to prevent
the disclosure of or to obtain a protective order for the Confidential Information; and provided further that Manufacturer shall reasonably
assist Merck in obtaining a protective order, shall make any required disclosures in consultation with Merck and shall clarify the confidential
nature of the disclosed Confidential Information.

 

		16.4	Exclusions to Confidentiality. Manufacturer shall not have any obligation
hereunder with respect to any Confidential Information if such Confidential Information (a) is, at the time of disclosure or becomes alter
disclosure, general or public knowledge through no breach of the Agreement by Manufacturer; (b) was, at the time of disclosure by Merck,
already known by Manufacturer, as established by written record; or (c) is received by Manufacturer from a Third Party having the right
to disclose same and who is not bound by a confidentiality agreement in favour of Merck or its Affiliates.

 

		16.5	Notification. In the event Manufacturer becomes aware or has knowledge
of any unauthorized use or disclosure of Confidential Information under Manufacturer’s control, Manufacturer shall promptly notify
Merck of such unauthorized use or disclosure and, thereafter, shall take all reasonable steps to assist Merck in attempting to minimize
any potential or actual damages or losses resulting from such unauthorized use or disclosure.

 

    29

     

    

 

		16.6	Return. Upon receipt of a written request from Merck, or upon termination
of this Agreement, Manufacturer shall promptly return to Merck all Confidential Information, including all reproductions and copies thereof
together with all internal material and documents generated by Manufacturer containing Confidential Information or references thereto
and Manufacturer shall delete all such Confidential Information and references thereto stored electronically. Notwithstanding the above,
Manufacturer may retain a single copy of any Confidential Information as is reasonably necessary for regulatory or insurance purposes,
subject to Manufacturer’s obligations of confidentiality under this Agreement.

 

		16.7	Public Announcements. Neither Party shall make any press nor other
public announcement concerning any aspect of this Agreement, unless the text of such announcement is first approved in writing by the
Parties to this Agreement. Provisions covering inspections and audits of Manufacturer, including with respect to the Manufacturing Site,
whether by Merck or a Regulatory Authority, are set forth in the Quality Agreement.

 

		16.8	Manufacturer Confidential Information. Merck acknowledges it may
receive confidential and proprietary information from Manufacturer including but not limited regarding its methodology, testing processes,
packaging and manufacturing techniques, data collection and/or data management techniques, commercial information, prices and contractual
terms (“Manufacturer Confidential Information”). Merck shall treat any Manufacturer Confidential Information in the
same confidential manner as Manufacturer is obliged to treat Confidential Information as set forth in this Agreement, except that Merck
may disclose such information as is requested by Regulatory Authorities or as is necessary to be included in regulatory filings or Product
Licenses (e.g. Drug Master Files).

 

		16.9	Data Processing Agreement. If and to the extent Personal Data is
processed on behalf of Merck by Manufacturer so that Manufacturer is acting as a “Processor”, the Data Processing Agreement
attached as Schedule 6 shall apply.

 

		16.10	Audit And Inspection Rights. Additional provisions covering inspections
and audits of Manufacturer, including with respect to the Manufacturing Site, whether by Merck or a Regulatory Authority, are set forth
in the Quality Agreement.

 

Article
17

WARRANTIES

 

		17.1	Mutual Representations and Warranties. Merck and Manufacturer each
represent and warrant to the other that:

 

		(a)	Organization and Authority. It has full corporate right, power and authority to enter into this
Agreement and to perform its respective obligations under this Agreement;

 

		(b)	No Conflicts or Violations. The execution and delivery of this Agreement by such Party and the
performance of such Party’s obligations hereunder (a) do not conflict with or violate any requirement of Applicable Laws existing
as of the Effective Date and applicable to such Party and (b) do not conflict with, violate, breach or constitute a default under, and
are not prohibited or materially restricted by, any contractual obligations of such Party or any of its Affiliates existing as of the
Effective Date; and

 

		(c)	Valid Execution. Such Party is duly authorized, by all requisite corporate action, to execute and
deliver this Agreement and the execution, delivery and performance of this Agreement by such Party does not require any shareholder action
or approval or the approval or consent of any Third Party, and the person executing this Agreement on behalf of such Party is duly authorized
to do so by all requisite corporate action.

 

    30

     

    

 

		17.2	Manufacturer Representations and Warranties for Manufacturing the Products.
In addition to the warranty pursuant to Section 9.1, Manufacturer represents and warrants to Merck that:

 

		(a)	Good Title, No Encumbrances. It will convey good title to the Products supplied under this Agreement,
free from any lawful security, interest, lien or encumbrances;

 

		(b)	Right to Manufacturer Background IP. It has the title and/or right to any and all Manufacturer
Background IP used to Manufacture the Products in accordance with this Agreement; and the Manufacture of the Products by Manufacturer
or its. Affiliates or by Merck or its Affiliates will not infringe the Intellectual Property or any other rights of any Third Party;

 

		(c)	Compliance Obligations. Merck intends to conduct its business in accordance with environmental,
labor and social standards and to abide by the standards set forth in the Human Rights Charter and Code of Conduct (including Merck
values) referred to under Schedule 3. Manufacturer shall comply, and shall ensure that its subcontractors comply, with reasonably
comparable environmental, labor and social standards. Manufacturer acknowledges that it is aware of the OECD Convention an Combating
Bribery of Foreign Public Officials in International Business Transactions and shall comply, and shall ensure that its subcontractors
comply, with its principles. Manufacturer shall not offer, promise, give, authorize or consent to the giving of money or anything of material
value to any person (i) with the purpose or effect of securing any improper advantage in order to obtain or retain business or (ii) to
induce or prevent the performance of an individual’s duties in violation of Applicable Law. Should Merck discover that Manufacturer
or its subcontractors are in breach of the foregoing, Merck may terminate this Agreement without notice.

 

		(d)	Compliance with Merck’s Responsible Sourcing Principles and Customs and Foreign Trade. It
will, and it will endeavour to ensure that its subcontractors, comply with internationally recognized fundamental environmental, labour
and social standards, as described in Merck’s Responsible Sourcing Principles referred to under Schedule 3. Upon request
of Merck, Manufacturer shall provide Merck with a supplier declaration as per Schedule 4.

 

		(e)	Bribery. It will neither offer to give nor give money or gifts to Merck employees or members of
their families in exchange for business from Merck; and

 

		(f)	Change of Control. It will provide prompt written notice to Merck in the event of any Change of
Control.

 

		17.3	Manufacturer Representations and Warranties for the Development Services.
Manufacturer represents and warrants to Merck that:

 

		(a)	Performance. The Services shall be performed in accordance with cGMP and Applicable Laws with respect
to the performance of Services;

 

    31

     

    

 

		(b)	Right to Manufacturer Background IP. It has the title and/or right to any and all Manufacturer
Background IP used to perform the Services in accordance with this Agreement; and the use by Manufacturer or its Affiliates of Manufacturer
Background IP will not infringe the Intellectual Property or any other rights of any Third Party.

 

		17.4	Merck Representations and Warranties. Merck represents and warrants
to Manufacturer that it holds all necessary Product Licenses with respect to the Products and that:

 

		(a)	Trial Authorizations. It holds all necessary Trial Authorizations to conduct the Trial.

 

		(b)	Right to Merck Background IP. It has the title and/or right to any and all Merck Background IP
supplied to Manufacturer in accordance with this Agreement for the Manufacture, labelling and packaging of the Products, and further that
it has the title and/or right to grant Manufacturer the right to use such Intellectual Property in accordance with the terms of this Agreement
and the use by Manufacturer or its Affiliates of Merck Background IP will not infringe the Intellectual Property or any other rights of
any third party.

 

Article
18

INDEMNITY

 

		18.1	Indemnification by Manufacturer. Manufacturer shall indemnify, hold
harmless and, upon request of Merck, defend Merck, its Affiliates and its and their directors, officers, representatives, shareholders,
employees and agents, and their respective successors and permitted assigns, from any and all Losses from any Third Party claims, proceedings,
actions or causes of actions (“Third Party Claims”) which arise out of (a) the faire of Products to meet the warranties
set forth in Section 9.1 and (b) any other breach by Manufacturer of any of its representations, warranties, covenants, agreements or
obligations under this Agreement, or the negligence, recklessness or wilful misconduct of Manufacturer (or its Affiliates or subcontractors)
in the performance the Services and any of its obligations hereunder; in each case except to the extent such Third Party Claim arises
out of matters contemplated in Section 18.2 (a) or (b) below. In the event a Third Party Claim is caused by both Party’s behaviour,
the amount of indemnification shall depend on the circumstances, in particular to what extend the Third Party Claim is caused mainly by
one or the other Party.

 

		18.2	Indemnification by Merck. Merck shall indemnify, hold harmless and,
upon request of Manufacturer, defend Manufacturer, its Affiliates and its and their directors, officers, representatives, shareholders,
employees and agents, and their respective successors and permitted assigns, from any and all Losses from any Third Party Claims which
arise out of (a) a breach by Merck of any of its representations, warranties, covenants, agreements or obligations under this Agreement
and (b) the negligence, recklessness or wilful misconduct of Merck (or its Affiliates or subcontractors) in the performance of its obligations
hereunder; in each case except to the extent such Third Party Claim arises out of result from matters contemplated in Section 18.1(a)
or (b) above. In the event a Third Party Claim is caused by both Party’s behaviour, the amount of Indemnification shall depend on
the circumstances, in particular to what extend the Third Party Claim is caused mainly by one or the other Party.

 

		18.3	No Consequential Damages. EXCEPT WITH RESPECT TO EACH PARTY’S
INDEMNIFICATION OBLIGATIONS UNDER SECTION 18.1 OR SECTION 18.2, AS APPLICABLE, AND/OR EXCEPT IN THE EVENT OF WILFUL MISCONDUCT AND GROSS
NEGLIGENCE, IN NO EVENT SHALL EITHER PARTY OR ANY OF ITS AFFILIATES FOR BREACH OF ITS OBLIGATIONS UNDER THIS AGREEMENT BE LIABLE TO THE
OTHER PARTY OR ANY OF ITS AFFILIATES FOR (I) ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL OR PUNITIVE DAMAGES, OR CLAIMS BROUGHT BY
[***] OR ANY OTHER THIRD PARTY HAVING SIGNED AN AGREEMENT WITH MERCK IN RELATION TO THE TRIAL, WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE,
STRICT LIABILITY OR OTHERWISE ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREIN OR ANY BREACH HEREOF.
FOR THE PURPOSES OF THIS CLAUSE “CONSEQUENTIAL DAMAGES” SHALL BE DEFINED AS LOSS OF PROFIT OR ANTICIPATED PROFIT, LOSS
OF PRODUCTION, LOSSES CAUSED BY BUSINESS INTERRUPTIONS, LOSS OF REVENUE AND LOSS OF GOODWILL OR REPUTATION AS WELL AS DAMAGES RESULTING
FROM REMOTE EVENTS THAT ARE VERY UNLIKELY TO HAPPEN, “PUNITIVE DAMAGES” SHALL BE DEFINED AS COMPENSATION CLAIMS THAT
EXCEED THE DAMAGE ACTUALLY INCURRED. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS AGREEMENT SHALL LIMIT EITHER PARTY FROM SEEKING OR
OBTAINING ANY REMEDY AVAILABLE UNDER APPLICABLE LAW, INCLUDING EQUITABLE REMEDIES, FOR ANY BREACH OF ITS CONFIDENTIALITY AND NON-USE OBLIGATIONS
UNDER ARTICLE 16.

 

    32

     

    

 

		18.4	Notification of Claims; Conditions to Indemnification Obligations.
As a condition to a Party’s right to receive indemnification under this ARTICLE 18, it shall: (a) promptly notify the other Party
as soon as it becomes aware of a claim or suit for which indemnification may be sought pursuant hereto; (b) cooperate, and cause the individual
indemnitees to cooperate, with the indemnifying Party in the defence, settlement or compromise of such claim or suit; and (c) permit the
indemnifying Party to control the defense, settlement or compromise of such claim or suit, including the right to select defence counsel.
In no event, however, may the indemnifying Party compromise or settle any Claim or suit in a manner which admits fault or negligence on
the part of the indemnified Party or any indemnitee without the prior written consent of the indemnified Party. Each Party shall reasonably
cooperate with the other Party and its counsel in the course of the defence of any such suit, claim or demand, such cooperation to include
without limitation using Commercially Reasonable Efforts to provide or make available documents, information and witnesses. The indemnifying
Party shall have no liability under this ARTICLE 18 with respect to Claims or suits settled or compromised without its prior written consent.

 

		18.5	Insurance. During the Term, each Party shall obtain and maintain,
at its sole cost and expense, insurance (including any self-insured arrangements) in types and amounts that are reasonable and customary
in the pharmaceutical and biotechnology industry for companies engaged in comparable activities in the jurisdiction where such activities
are being performed. Manufacturer shall add Merck as an additional insured on any product liability and comprehensive general liability
policy carried by Manufacturer. Without prejudice to the foregoing, Manufacturer shall maintain a minimum product liability insurance
coverage of [***] per occurrence, with a deductible of a maximum of [***]. It is understood and agreed that this insurance shall not be
construed to limit either Party’s liability with respect to its indemnification obligations hereunder. Each Party will, except to
the extent self-insured, provide to the other Party upon request a certificate evidencing the insurance such Party is required to obtain
and keep in force under this Section 18.5.

 

Article
19

TERM AND TERMINATION

 

		19.1	Term. This Agreement shall commence on the Effective Date and continue
for an initial period of [***] (the “Initial Term”), and thereafter shall automatically renew for further successive
periods of [***] each (the “Renewal Term” and together with the Initial Term, the “Term”), unless
terminated earlier as provided for elsewhere in this Agreement. Either Party shall have the right to terminate this Agreement at the end
of the Initial Term or at the end of a Renewal Term by providing the other Party with no less than [***] prior written notice.

 

    33

     

    

 

		19.2	Termination On Failure of a Condition Precedent under Section 2.2.
In case one of the events described in Section 2.2 is not met, Merck shall have the right to terminate this Agreement with immediate effect
by sending a written notice to Manufacturer in accordance to Section 23.10.

 

		19.3	Termination for Convenience. Merck shall have the right to terminate
this Agreement at any time in its sole discretion by giving [***] advance written notice to Manufacturer.

 

		19.4	Patient Safety. Merck may terminate the Agreement (a) at any time
if termination is reasonably considered necessary by Merck by giving written notice to the Manufacturer in the interest of the health
and well-being of the Trial Subjects, in which case notice of termination shall have immediate effect and (b) on a Product-by-Product
basis by giving [***] advance written notice to Manufacturer if Merck decides to withdraw the Product from the market.

 

		19.5	Change of Control Term. Manufacturer shall provide notice to Merck
as soon as possible after a Change of Control with a company developing or commercializing [***] and upon receipt of such notification
Merck shall have the right to terminate this Agreement with immediate effect.

 

		19.6	Regulatory Authority Warning Letter. Merck may terminate the Agreement
immediately upon written notice to Manufacturer if Manufacturer is subject to any Regulatory Authority warning letter or sanction.

 

		19.7	Termination for Breach. If either Party to this Agreement shall have
materially breached or defaulted in the performance of any of its obligations and does not remedy the breach within [***] of notice from
the other Party to do so (if capable of remedy) the non-breaching Party may terminate this Agreement immediately by written notice to
the Party in breach. It is understood and agreed by the Parties that the non-respect by Manufacturer of its Yearly Capacity Reservation
obligation as provided for in Section 2.6, is considered a material breach under this Agreement.

 

		19.8	Termination for Late Delivery. If Manufacturer becomes more than
[***] liable under Section in any calendar year, Merck shall have the right to terminate this Agreement upon written notice to Manufacturer.
The provisions of this Section 19.8 are non-exclusive and without prejudice to the payment of penalties pursuant to Section 5.6 above
or any other remedy under this Agreement or Applicable Law.

 

		19.9	Termination for Force Majeure Event. Notwithstanding anything to
the contrary contained in this Agreement, in the event a Force Majeure Event shall have occurred and be continuing for [***], the Party
not suffering such Force Majeure Event shall be entitled to terminate this Agreement effective immediately upon written notice to the
Party suffering such Force Majeure Event.

 

		19.10	Termination for Reasons of Insolvency or Termination of Business Activities.
Either Party shall be entitled to terminate this Agreement if the other Party becomes insolvent or is the subject of a petition in bankruptcy
whether voluntary or involuntary or of any other proceeding under bankruptcy, insolvency or similar laws, makes an assignment for the
benefit of creditors, is named in such a petition, or its property is subject to a suit for the appointment of a receiver, or is dissolved
or liquidated. Such termination right may be exercised without the need for written notice within [***] following the date as of which
the Party entitled to terminate receives knowledge of such insolvency or termination of business activities by the other Party.

 

    34

     

    

 

Article
20

EFFECTS OF TERMINATION

 

		20.1	Termination Due to Reasons other than Manufacturer Default or Insolvency.
Upon expiration or termination of this Agreement other than in case of termination by Merck pursuant to Sections 19.5, 19.6, 19.7, 19.8
or 19.10, Merck shall, by written notice to Manufacturer: (i) request Manufacturer to execute outstanding Work Orders or Purchase Orders,
and, unless the Products delivered to Merck do not comply with the terms of this Agreement due to Manufacturer’s breach of the warranties
set out in Section 9.1, Merck shall pay Manufacturer in accordance with the terms of this Agreement, or (ii) cancel any outstanding Work
Order or Purchase Order, pay the Price for the cancelled Manufacturing Runs and reimburse Manufacturer for any actual costs in executing
such Work Order or Purchase Order, provided that Manufacturer shall use Commercially Reasonable Efforts to mitigate such actual costs.
For the avoidance of doubt, Section 4.8 shall apply, i.e. Merck shall only be obliged to pay part of the Price for a Manufacturing Run
set out in a Work Order depending on the time of receipt of Merck’s termination notice.

 

		20.2	Termination Due to Manufacturer Default or Insolvency. Upon termination
of this Agreement by Merck pursuant to Sections 19.5 19.6, 19.7, 19.8 or 19.10, Merck shall, by written notice to Manufacturer: (i) request
Manufacturer to execute outstanding Work Orders or Purchase Orders, and provided that the Products delivered to Merck comply with the
terms of this Agreement, Merck shall pay Manufacturer in accordance with the terms of this Agreement, or (ii) cancel outstanding Work
Orders or Purchase Orders without any liability to Merck.

 

		20.3	Termination for any Reason. Upon expiration or termination of this
Agreement for any reason, each Party shall return or destroy all of the other Party’s Confidential Information which it has in its
possession or under its control, unless and to the extent the Party is under a statutory obligation to keep such Confidential Information.

 

		20.4	Termination On Failure of a Condition Precedent under Section 2.2 or
for Convenience. Termination of this Agreement by Merck pursuant to Section 19.2 or Section 19.3 shall not give rise to any claim
for Losses by Manufacturer against Merck. For the avoidance of doubt, termination pursuant Section 19.2, unless due to a Manufacturer’s
failure to perform its obligations under this Agreement, and Section 19.3 shall not affect Merck’s obligation to fully pay for Manufacturing
Runs set out in the Firm Zone or Merck’s obligations under any open Work Order or Purchase Order in accordance to Sections 4.6 and
4.8.

 

		20.5	Ongoing Supply Obligations. In the event of expiration or termination
of this Agreement pursuant to ARTICLE 19 hereabove, except if this Agreement is terminated by Merck pursuant to Section 19.1 or by Manufacturer
for any reason, Manufacturer shall continue to supply Merck with Merck’s new Work Orders or Purchase Orders after the expiration
date or termination date of this Agreement, if Merck has not identified and fully registered with the competent Regulatory Authorities
a new Manufacturer of a replacement product. Such obligation of Manufacturer shall continue until the earlier of (i) successful completion
of the technical transfer pursuant to Section 20.8, and (ii) notification by Merck to the Manufacturer that it has identified and duly
registered with the competent Regulatory Authorities a new manufacturer of the Products.

 

		20.6	Accrued Rights and Surviving Obligations. Termination or expiration
of this Agreement for any reason shall be without prejudice to any rights that have accrued to the benefit of any Party prior to such
termination or expiration. Such termination or expiration shall not relieve any Party from obligations which are expressly or by implication
intended to survive termination or expiration of this Agreement and shall not affect or prejudice any provision of this Agreement which
is expressly or by implication provided to come into effect on, or continue in effect after, such termination or expiration.

 

    35

     

    

 

		20.7	Regulatory Assistance. After expiration or termination of this Agreement,
Manufacturer agrees to provide Merck with reasonable support in relation to any investigation required by any Regulatory Authority with
respect to Manufacture of the Products carried out at the Manufacturing Site during the Term, provided that Merck shall reimburse Manufacturer
for its reasonable costs in providing such assistance (other than in case of Merck’s termination under Sections 19.6, 19.7 or 19.10).

 

		20.8	Technical Transfer Assistance. For a period of [***] following expiration
or termination of this Agreement for any reason, Manufacturer will provide, upon the request of Merck, its reasonable support and cooperation
in transferring the then-current manufacturing process of the Product to an alternative site, designated by Merck. Manufacturer shall
be entitled to charge Merck for its reasonable costs in supporting the technical transfer of the Products, at the Agreed Hourly Rate based
on a written and accepted quotation, provided, however, if the technical transfer is requested by Merck following its termination of this
Agreement under Sections 19.6, 19.7 or 19.10 then the Manufacturer shall provide the above technical transfer services free-of-charge.
Additionally, in connection with the technical transfer assistance provided pursuant to this Section 20.8, Manufacturer shall grant to
Merck and its Affiliates and designees a perpetual, fully-paid, non-exclusive, royalty-free license, with the right to sublicense, under
any Manufacturer intellectual Property which is reasonably necessary for the manufacture of each Product. Manufacturer’s obligations
to support a technical transfer shall continue until such time as Merck, or its designee, successfully manufactures a validated Batch
of each Product.

 

Article
21

DISASTER RECOVERY AND BUSINESS CONTINUITY

 

Manufacturer shall provide
Merck prior to the commencement of the first Manufacturing Run under a Purchase Order with a true, correct and complete copy of Manufacturer’s
business continuity plan (the “BCP”) which provides for, among other things, the high level design and processes for
disaster recovery and business continuity for Manufacturer. The BCP shall be revised and updated by Manufacturer from time to time, but
in no event less than every [***]. The Parties shall meet periodically, as specified by Merck, to discuss and analysis the status of the
BCP. Manufacturer shall provide a written report to Merck for such discussions and analysis which shall analysis the effectiveness of
the applicable BCP, propose necessary changes, suggest improvements, and provide an updated risk assessment for the activities to which
the BCP relates.

 

Article
22

DISPUTE RESOLUTION

 

		22.1	Disputes. The Parties recognize that disputes as to certain matters
may from time to time arise during the Term which relate to either Party’s rights and/or obligations hereunder. It is the objective
of the Parties to establish under this ARTICLE 22 procedures to facilitate the resolution of disputes arising under this Agreement (other
than any disputes relating to matters which under this Agreement Merck has sole decision-making authority and/or discretion (each, a “Non-Escalable
Dispute”), in which case, such matter shall be determined by Merck and shall not be part of the dispute resolution procedure
set forth in this ARTICLE 22) in an expedient manner by mutual cooperation and without resort to litigation. In the event that the Parties
are unable to resolve such dispute through diligent review and deliberation within [***] from the day that one Party had designated the
issue as a dispute in written notice to the other Party, then either Party shall have the right to escalate such matter to the Executive
Officers as set forth in Section 22.2.

 

    36

     

    

 

		22.2	Escalation to Executive Officers. Either Party may, by written notice
to the other Party, request that a dispute (other than a Non-Escalable Dispute) that remains unresolved for a period of [***] as set forth
in Section 22.1 arising between the Parties in connection with this Agreement be resolved by the Executive Officers, within [***] alter
referral of such dispute to them. If the Executive Officers cannot resolve such dispute within [***] after referral of such dispute to
them, then, at any time after such [***] period, either Party may proceed to enforce any and all of its rights with respect to such dispute
in accordance with this Agreement.

 

		22.3	Injunctive Relief. No provision herein shall be construed as precluding
a Party from bringing an action for injunctive relief or other equitable relief prior to the initiation or completion of the above procedure.

 

Article
23

MISCELLANEOUS PROVISIONS

 

		23.1	Relationship of the Parties. Nothing in this Agreement is intended
or shall be deemed, for financial, tax, legal or other purposes, to constitute a partnership, agency, joint venture or employer-employee
relationship between the Parties.

 

		23.2	Assignment.

 

		(a)	Assignment Generally. Except as expressly provided herein, neither this Agreement nor any interest
hereunder shall be assignable, nor any other obligation delegable, by Manufacturer without the prior written consent of Merck (not to
be unreasonably withheld or delayed).

 

		(b)	Assignment by Merck. Merck may assign this Agreement, in whole or in part, to any Affiliate or
Third Party without the consent of Manufacturer. Merck shall give written notice to Manufacturer promptly following any such assignment.

 

		(c)	Continuing Obligations. No assignment under this Section 23.2 shall relieve the assigning Party
of any of its responsibilities or obligations hereunder and, as a condition of such assignment, the assignee shall agree in writing to
be bound by all obligations of the assigning Party hereunder. This Agreement shall be binding upon the successors and permitted assigns
of the Parties.

 

		(d)	Void Assignments. Any assignment not in accordance with this Section 23.2 shall be void.

 

		23.3	Performance and Exercise by Affiliates. Merck shall have the right
to have any of its obligations hereunder performed, or its rights hereunder exercised, by, any of its Affiliates and the performance of
such obligations by any such Affiliate(s) shall be deemed to be performance by Merck; provided, however, that Merck shall be responsible
for ensuring the performance of its obligations under this Agreement and that any failure of any Affiliate performing obligations of Merck
hereunder shall be deemed to be a failure by Merck to perform such obligations.

 

    37

     

    

 

		23.4	Technical Managers. Each Party will notify the other in writing with
the name of a technical manager who will be responsible for dealing with all matters relevant to this Agreement. The appointment of Manufacturer’s
technical manager shall be subject to approval of Merck, not to be unreasonably withheld or delayed. Manufacturer shall replace its technical
manager upon Merck’s request for reasonable cause within [***]. Unless otherwise mutually agreed, the technical managers and other
appropriate representatives from each Party shall endeavor to meet no less than once every [***] to discuss matters relevant to the Manufacture
and supply of Products hereunder.

 

		23.5	Occurrence of Force Majeure Event. If any Force Majeure Event occurs
in relation to either Party which affects or may affect the performance of any of its obligations under this Agreement, it shall use all
Commercially Reasonable Efforts to mitigate the effects of such delay or prevention upon the performance of its obligations under this
Agreement, promptly notify the other Party as to the nature and extent of such Farce Majeure event; and resume performance of its obligations
as soon as reasonably possible alter the removal of the cause of the delay or prevention. Neither Party shall be deemed to be in breach
of this Agreement, or shall be otherwise liable to the other Party, by reason only of any delay in performance, or the non-performance
of any of its obligations hereunder, to the extent that the delay or non-performance is due to any Force Majeure Event of which it has
duly notified the other Party, and the time for performance of that obligation shall be extended accordingly. Without limiting Merck’s
right to terminate this Agreement pursuant to Section 19.9, if the performance by either Party of any of its obligations under this Agreement
is prevented or delayed by a Force Majeure Event for a continuous period in excess of [***], the Parties shall enter into bona fide discussions
with a view to alleviating its effects, or to agreeing upon such alternative arrangements as may be fair and reasonable in the circumstances.

 

		23.6	No Trademark Rights. No right, express or implied, is granted by
this Agreement to a Party to use in any manner the name or any other trade name or trademark of the other Party in connection with the
performance of this Agreement or otherwise.

 

		23.7	Entire Agreement of the Parties; Amendments. This Agreement and the
Schedules hereto constitute and contain the entire understanding and agreement of the Parties in respect of the subject matter hereof
and cancel and supersede any and all prior negotiations, correspondence, understandings and agreements between the Parties, whether oral
or written, regarding such subject matter. In the event of any conflict or contradiction between this Agreement and a Schedule, the provisions
of this Agreement shall prevail, except with respect to conflicts or contradiction for matters of quality or technical nature, in which
case the applicable Quality Agreement shall prevail. No waiver, modification or amendment of any provision of this Agreement shall be
valid or effective unless made in a writing referencing this Agreement and signed by a duly authorized officer of each Party.

 

		23.8	Captions. The captions to this Agreement are for convenience only,
and are to be of no forte or effect in construing or interpreting any of the provisions of this Agreement.

 

		23.9	Governing Law and Arbitration. This Agreement shall be governed by
and interpreted in accordance with the laws of Germany, excluding application of any conflict of laws principles that would require application
of the Law of a jurisdiction outside of Germany and further excluding the UN Convention an Contracts for the International Safe of Goods
(CISG). All disputes arising out of or in connection with this Agreement or its validity shall be submitted to the International Court
of Arbitration and shall be finally settled in accordance with the Arbitration Rules of the International Chamber of Commerce. The place
of arbitration shall be Geneva, Switzerland. The number of arbitrators shall be three (3). The language of the arbitral proceedings shall
be English.

 

    38

     

    

 

		23.10	Notice. Any notice to be given by either Party under or in connection
with this Agreement to the other Party must be in writing in English and shall be delivered by hand or by courier. A copy by fax or by
email shall be sent to the addresses set out below (or such other address or number as may be notified to the other Party from time to
time):

 

Manufacturer:

 

Address: Richter-Helm BioLogics GmbH
&Co.KG., [***]

 

Fax: [***]

 

Email: [***]

 

Attention: [***]

 

Merck:

 

Address: Merck Serono S.A.—[***]

 

Phone: [***]

 

Email: [***]

 

Attention: [***]

 

With copy to: Legal Department

 

Unless there is evidence that it was
received earlier, notices sent in accordance with this Section 23.10 are to be deemed to have been received: if delivered by hand or by
courier, when left at the address referred to above; or if sent by fax or email, when transmitted, provided that if deemed receipt occurs
before 9am on a Working Day the notice shall be deemed to have been received at 9am on that day, and if deemed receipt occurs alter 5pm
on a Working Day, or on a day which is not a Working Day, the notice shall be deemed to have been received at 9am on the next Working
Day.

 

		23.11	Waiver. A waiver by either Party of any of the terms and conditions
of this Agreement in any instance shall not be deemed or construed to be a waiver of such term or condition for the future, or of any
other term or condition hereof All rights, remedies, undertakings, obligations and agreements contained in this Agreement shall be cumulative
and none of them shall be in limitation of any other remedy, right, undertaking, obligation or agreement of either Party.

 

		23.12	Severability. When possible, each provision of this Agreement will
be interpreted in such manner as to be effective and valid under Applicable Law, but if any provision of this Agreement is held to be
prohibited by or invalid under Applicable Law, such provision will be ineffective only to the extent of such prohibition or invalidity,
without invalidating the remainder of this Agreement. The Parties shall make a good faith effort to replace the invalid or unenforceable
provision with a valid one which in its economic effect is most consistent with the invalid or unenforceable provision.

 

		23.13	No Implied License. Except as set forth in Section 3.3, no right
or license is granted to Manufacturer hereunder by implication, estoppel, or otherwise to any know-how, patent or other Intellectual Property
owned or controlled by Merck or its Affiliates.

 

		23.14	Interpretation. The words “include,” “includes”
and “including” shall be deemed to be followed by the phrase “without limitation.” All references herein to Articles,
Sections, and Schedules shall be deemed references to Articles and Sections of, and Schedules to, this Agreement unless the context shall
otherwise require. Unless the context otherwise requires, countries shall include territories.

 

		23.15	Counterparts. This Agreement may be executed in counterparts, each
of which will be deemed an original, and all of which together will be deemed to be one and the same instrument. A facsimile or a portable
document format (PDF) copy of this Agreement, including the signature pages, will be deemed an original.

 

[SIGNATURE PAGE FOLLOWS]

 

    39

     

    

 

IN WITNESS WHEREOF, the Parties
have caused this Agreement to be executed, by duly authorized representatives, as of the Effective Date.

 

	Merck KGaA	 	Richter-Helm
    Biologics GmbH & Co. KG
	 	 	 
	[***]	 	[***]
	By:	[***]	 	By:	[***]
	Title:	[***]	 	Title: 	[***]
		 	 
	[***]	 	[***]
	By:	[***]	 	By: 	[***]
	Title: 	[***]	 	Title:	[***]

 

 

40Exhibit 10.12

 

Certain confidential information contained in this document, marked
by brackets as [***], has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
In addition, certain personally identifiable information contained in this document, marked by brackets as [***], has been omitted from
this exhibit pursuant to Item 601(a)(6) under Regulation S-K.

 

AMENDMENT NO.2

 

TO THE CLINICAL AND COMMERCIAL MANUFACTURING
AGREEMENT

 

This Amendment No.2 (the “Amendment No.2”),
is made and entered into, as of November 20th, 2020 (“Effective Date”), by and between:

 

Richter Helm Biologics GmbH & Co.KG, a corporation organized
under the laws of Germany having a place of business at [***] (“Manufacturer”), and

 

Merck Healthcare KGaA, a corporation organized under the
laws of Germany and having a place of business at Frankfurter Strasse 250, 64293 Darmstadt, (“Merck”).

 

Manufacturer and Merck may be referred to herein individually
as a “Party” or, collectively, as “Parties.”

 

WITNESSETH

 

WHEREAS, Merck, and Manufacturer have entered into
a Clinical and Commercial Manufacturing Agreement dated as of October 15th, 2018 and amended by Amendment No.1 dated as of
December 6, 2019 (hereinafter referred to as the “Agreement”);

 

WHEREAS, the Agreement was transferred from Merck
KGaA to Merck Healthcare KGaA an 1st April 2019 as part of a business restructuring of Merck KGaA;

 

WHEREAS, the Parties wish to amend the Agreement
in accordance with the terms set forth in this Amendment;

 

NOW, THEREFORE, in consideration of the premises
and the mutual covenants herein contained and eventual addenda, the Parties agree to amend the existing Agreement, with effect from the
Effective Date, as follows:

 

ARTICLE 1— DEFINITIONS

 

Capitalized terms not otherwise defined herein shall have
the meanings given in the Agreement.

 

ARTICLE 2 — AMENDMENTS

 

As of the Effective Date of this Amendment No.2, the Agreement
shall be amended as follows:

 

2.1 The Parties hereby
acknowledge and agree to delete Article 5.9 (Key Performance Indicators) in its entirety and replace it by the following Article 5.9
(Key Performance Indicators):

 

     

     

    

 

5.9 Key Performance Indicators.

 

The Parties agree to measure Manufacturer’s
performance of its Development (when applicable) & Commercial Manufacturing Services through the establishment of Key
Performance Indicators (“KPIs”) set forth in Schedule 2. As long as Manufacturer only delivers up to [***]
commercial Batches per year, Manufacturer shall provide Merck with [***] reports out of its performance based on the KPIs. From
[***] Batches per year, the reports should occur [***]. The Parties may agree on additional KPIs by means of further amendments to
this Agreement. The Parties shall agree upon the relative importance of the KPIs by classifying each KPI with a designation of
“minor”, “major” or “critical”. The Parties shall agree in good faith by [***] of each [***],
(beginning with the [***] of the Agreement), the performance level objectives of Manufacturer for the following year. The
performance level objectives shall be established for individual KPIs and for overall performance and on the basis of actual, past
performance, and shall be expressed in measurable values. In addition, minimum acceptance levels shall be agreed upon for all
critical KPIs and for overall performance. Manufacturer shall use all Commercially Reasonable Efforts to ensure that its performance
does not fall below these minimum acceptance levels. Notwithstanding Manufacturer’s use of all Commercially Reasonable
Efforts, if at any time Manufacturer’s overall performance or performance for critical KPIs falls below the established
minimum acceptance levels, Manufacturer shall promptly take corrective action to cure such under-performance.”

 

2.2 The Parties hereby
acknowledge and agree to delete in its entirety Schedule 2 (KPIs) and replace it by a new Schedule 2 (KPIs) attached to this
Amendment No.2.

 

2.3 The Parties hereby
acknowledge and agree to add to Schedule 5 — DEVELOPMENT SERVICES, DELIVERABLES & TIMELINES an additional sub-section
entitled “Performance of the HSA binding Assay (ELISA) ” as follows:

 

[***]

 

ARTICLE 3 — NO OTHER AMENDMENTS

 

Except as expressly amended hereby,
all of the terms and conditions of the Agreement shall remain unchanged and in full force and effect.

 

IN WITNESS WHEREOF, the Parties
have caused this Amendment No.2 to be executed by their respective duly authorized officers or representatives in two (2) copies, each
an original. This Amendment No.2 may be executed via facsimile or “.pdf’ file and in counterparts, each of which shall be
signed by each of the contracting parties and deemed an original, but all of which together shall constitute one and the same instrument.

 

	MERCK HEALTHCARE
    KGAA	 	Richter
    Helm Biologics GmbH & Co.KG
	 	 	 
	[***] 	 	[***] 
	By: 	[***]	 	By: 	[***]
	Title: 	[***]	 	Title: 	[***]
	 	 	 
	[***] 	 	[***] 
	By: 	[***]	 	By: 	[***]
	Title: 	[***]	 	Title: 	[***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}]]